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Abstract  
 
The pathogenesis of non-alcoholic steatohepatitis (NASH) is thought to occur 
through interacting mechanisms of cellular stress. Lipids accumulate within 
hepatocytes, making cells more susceptible to insult and less able to respond to 
challenges, leading to progression from simple steatosis to inflammation.  
 
Endoplasmic reticulum (ER) stress occurs when mis-folded proteins accumulate 
in the ER lumen and cellular requirement exceeds the capacity of the ER to 
modify proteins. ER stress activates pathways that act to attenuate stress or 
prompt apoptosis if ER homeostasis cannot be achieved. The transcription factor 
nuclear receptor (erythroid-derived 2)-like 2 (Nrf2) is a master regulator that 
orchestrates the response to oxidative stress by inducing expression of 
cytoprotective genes. Understanding interactions between oxidative and ER 
stress may allow further understanding of the pathogenesis of NASH. 
 
The role of Nrf2 in response to ER stress was investigated using mouse epithelial 
fibroblasts, comparing WT to Nrf2-/- and cells with increased Nrf2 activity. ER 
stress was induced and expression of ER stress response proteins was analyzed.  
 
Results demonstrate that Nrf2-/- cells have increased expression of ER stress 
response proteins under basal conditions compared to WT. The response to ER 
stress also varied with cellular Nrf2 status: Maximal response to glucose 
deprivation occurred at 4 hours in both WT and Nrf2-/- cells, but occurred at 
6hours in cells with increased Nrf2 availability.  The magnitude of the response 
was smaller in Nrf2-/- cells, suggesting that Nrf2-/- cells have less ability to 
respond to ER stress. It is proposed that Nrf2 is involved in a negative feedback 
mechanism, whereby increased Nrf2 activity helps to alleviate ER stress and 
subsequently down-regulates the ER response.  
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Chapter 1 Introduction 
1.1 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
1.1.1 Overview  
Non-alcoholic fatty liver disease (NAFLD) is a condition characterised by the 
accumulation of lipids within hepatocytes.  NAFLD encompasses a spectrum of 
histopathological severity, ranging from simple steatosis to increasing levels of 
inflammation, known as non-alcoholic steatohepatitis (NASH), which can occur 
with or without fibrosis (1).  
 
Historically, NASH was thought to be related to undisclosed alcohol intake 
because of the histological similarities with alcoholic liver disease (ALD) (2).  
However, the development of fatty liver in confirmed non-drinkers, particularly 
associated with obesity, type II diabetes mellitus (TIIDM) and hyperlipidaemia 
was increasingly recognised (2).  The term NASH was first used to characterise 
this distinct condition in the 1980s by Ludwig et al. in a classical case series of 
20 patients with documented histopathological findings (3).  Since this time 
NAFLD and NASH have become widely accepted and are generally considered 
to be the hepatic manifestations of obesity and metabolic dysfunction. 
1.1.2 The natural history of NAFLD 
1.1.2.1 Associations and epidemiology 
NAFLD is frequently associated with a sedentary lifestyle, calorific excess and 
visceral adiposity; it is therefore unsurprising that alongside trends in obesity, 
NAFLD is becoming increasingly common (1, 4, 5). An increase in the fructose 
component in the western diet has been postulated as a possible cause of the 
increasing prevalence of this condition (6).  NAFLD is now considered to be the 
most common cause of chronic liver disease, with a global prevalence of 
approximately 25% (1).  The proportion of patients with NAFLD who have 
NASH varies between populations, ranging from 6-29%; however this reaches 
almost 60% in cases where biopsy is clinically indicated (7).  NASH has become 
the second leading cause of liver transplantation in the United States (7).  
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1.1.2.2 Disease progression and complications 
A significant proportion of NAFLD patients develop progressive liver disease, 
which in the most severe cases can result in fibrosis, cirrhosis and end stage liver 
failure (1).  NASH, and fibrosis in particular, is also associated with the 
development of hepatocellular carcinoma (HCC) (1).  The natural history of 
NAFLD often follows a gradual process of increasing severity, however the 
NAFLD population is heterogeneous and a subgroup of patients experiences a 
more rapid deterioration (1).  Simple steatosis has typically more benign 
outcomes, however, up to 4% of patients still develop cirrhosis within a 20-year 
period (1).  Patients with NASH characteristically have more aggressive disease, 
with an increased risk of complications and more rapid development of cirrhosis 
(1).  
 
There are many factors that influence disease progression, including individual 
variation, genetic and environmental factors and comorbid disease.  NAFLD can 
occur as part of the metabolic syndrome, a multisystem disorder of metabolic 
derangement and excess comprising obesity, hypertension, dyslipidaemia and 
insulin resistance.  TIIDM is a risk factor for more severe disease, and male 
patients with co-existing metabolic syndrome are at an increased risk of HCC 
development (1). 
1.1.2.3 Population health impact 
Despite the fact that only a small proportion of patients develop severe 
complications of NAFLD, the high prevalence of disease within the population 
creates a significant public health burden. Patients with NAFLD frequently have 
comorbid metabolic disease and NASH is associated with an increased 
cardiovascular morbidity and mortality (7).   Therefore many patients have 
multiple health issues and a significant proportion may progress to serious 
complications including, but not limited to, end stage liver disease. 
 
Due to the increasing burden of obesity associated liver disease, delineation of 
the biochemical pathways underlying the pathophysiology and disease 
progression of steatosis to NASH is of great importance.  Insight into this area 
could aid identification of new, more accurate diagnostic methods and 
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understanding key molecular events may allow the development of targeted drug 
treatments.  Although it is likely that multiple factors contribute to NAFLD, 
establishing the mechanism of liver injury is also key to allow prevention 
strategies.    
1.1.3 Current Management of Patients with NAFLD 
1.1.3.1 Clinical Presentation and diagnosis  
NAFLD can be asymptomatic, and is often discovered incidentally following 
abnormalities in routine biochemistry (2, 8).  Symptomatic patients may present 
with right upper quadrant pain, or nonspecific complaints such as fatigue (2, 8).  
Investigations typically demonstrate mild to moderate increases in serum 
transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST), which are nonspecific indicators of hepatocyte damage, and findings of 
increased hepatic echogenicity on ultrasound scan supports steatosis.  Diagnosis 
of NAFLD is clinical, after the exclusion of other potential aetiologies including 
autoimmune, drug related, ALD and viral hepatitis.  Diagnosis of NASH requires 
histological evidence of inflammation, in the presence of steatosis without other 
causes of liver disease (8).   
1.1.3.2 Liver biopsy and histopathological features 
Liver biopsy for histological assessment is considered to be the gold standard for 
diagnosis of NASH, however this is associated with small but significant 
mortality risk, and is therefore performed only in cases when clinically necessary, 
or for research purposes (8).  NAFLD is histologically defined as the presence of 
visible lipid droplets in >5% of hepatocytes and features of NASH include fatty 
changes, lobular inflammation, Mallory-Denk bodies, fibrosis and necrosis (9).  
The NAFLD activity score (NAS) is a frequently used research tool to score 
histological severity of disease (10).  
1.1.3.3 Follow up and management  
Management of fatty liver primarily involves lifestyle modifications of diet and 
exercise to facilitate weight loss, with major improvements typically occurring 
with >10% weight loss (8, 11, 12).  There are a number of scoring tools that can 
be used to stratify patients and identify those most at risk of disease progression 
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and fibrosis; these include the Enhanced Liver Fibrosis Score, NAFLD fibrosis 
score, Fibrosis-4 index and AST to platelet ratio (8, 11).  There are currently no 
targeted treatments for NAFLD, however some studies have demonstrated 
modest improvements in histological features and serum enzymes with vitamin E 
and peroxisome proliferated activating receptor γ (PPARγ) agonists such as 
pioglitazone (11).  In the UK, guidelines recommend these treatments be 
considered in patients with advanced fibrosis (8).  Research into potential 
treatments is on going and includes therapies used in managements of TIIDM 
such as glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 
4 (DPP-4) inhibitors as well as CC-chemokine receptor antagonists and farnesoid 
X receptor (FXR) agonists (11, 12).  Evidence from the FLINT trial, a 
multicentre, randomised placebo-controlled clinical trial in 283 NASH patients 
demonstrated that obeticholic acid, a synthetic bile acid and FXR agonist 
significantly improved histological features compared to placebo, with the main 
reported adverse effect of pruritus (13).  Although this result seems promising, 
further evidence on efficacy, benefits and safety is required (13). 
1.1.4 Current hypotheses of pathology in NAFLD 
There has been much interest in characterising the key pathways underpinning 
the development of NAFL and NASH, reviewed in (14).  NAFLD is a 
heterogeneous condition, with genetic and environmental factors further 
influencing an individual’s susceptibility to disease development and progression 
(12).  The predominant theory of pathogenesis is the multiple hit model, whereby 
insulin resistance and hepatic storage of triacylglycerides is compounded by 
further cellular insult, leading to inflammation and fibrosis (15, 16).  Areas under 
study include the inflammatory response, intestinal microbiome, adipose tissue 
dysfunction, mitochondrial dysfunction, nutritional factors and the role of insulin 
resistance (17).  
 
The initial accumulation of fat in hepatocytes results from an imbalance in lipid 
homeostasis alongside adipose tissue inflammation and dysfunction(14).  
Steatotic hepatocytes are more vulnerable to damage, and cellular dysfunction 
can be exacerbated by further insults such as direct lipotoxicity, oxidative stress, 
endoplasmic reticulum (ER) stress, and mitochondrial dysfunction (14).  
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Damaged and apoptotic hepatocytes release cellular components.  These, along 
with proinflammatory cytokines (e.g. tumour necrosis factor α (Tnfα)), 
adipokines and bacterial endotoxins, activate resident hepatic macrophages, 
Kupffer cells (14).  This results in further cytokine and chemokine release, 
recruitment of monocytes and amplification of the proinflammatory response 
(14).  The components that induce inflammation can also prime and activate 
hepatic stellate cells (HSC), which transdifferentiate to a myofibroblast 
phenotype, promoting collagen production and fibrosis (14). The following 
sections will provide more detail on the molecular pathways1 involved in lipid 
homeostasis, oxidative stress and ER stress.  
 
 
 
Figure 1.1 Mechanisms potentially contributing to the pathogenesis of fatty 
liver disease, adapted from (15)  
 
                                                
1 For clarity, because this project has utilised mouse tissues and a murine cell line, pathways will 
be described using standard murine gene/protein abbreviations, unless discussing specific studies 
in human tissues.   
 20 
1.2 LIPID PATHWAYS 
Energy homeostasis relies on the balance of intake and expenditure: Calorific 
excess results in an anabolic state promoting synthesis and storage, for example 
the storage of fatty acids as triglycerides in adipose tissue.  In contrast, nutrient 
deprivation results in a catabolic state promoting the mobilisation and 
metabolism of energy stores to provide substrates for adenosine triphosphate 
(ATP) production.  The liver, endocrine pancreas and adipose tissue are highly 
involved in regulating the response to metabolic status, which relies on 
coordinated interactions and responses between these organs.   
1.2.1 Lipid homeostasis in the liver 
The liver is the primary site of lipid processing and esterification, and lipid 
homeostasis is perturbed in NAFLD.  Lipid input is derived from three main 
sources: Dietary intake in the form of chylomicrons, free fatty acids mobilised 
and released from existing adipose stores, and fatty acids newly synthesised from 
carbohydrates during de novo lipogenesis (14, 18).  Lipid output occurs through 
export, for example into plasma as lipoproteins, incorporation into cellular 
components and metabolism via beta-oxidation (18).  Uptake of circulating free 
fatty acids into hepatocytes is proportional to serum concentration and occurs 
through passive diffusion or facilitated transport by fatty acid transport protein 
(Fatp) and fatty acid translocase (Fat/Cd36) (18).  After entering the cell, fatty 
acids bind to fatty acid binding protein (Fabp) or to acyl-Co-enzyme A (acyl-
CoA) via acyl-CoA synthetase (Acs) enzymes, the latter producing fatty-acyl-
CoA (18).  These bound forms are then processed depending on the nutritional 
and energy status of the cell (18).    
 
In states of positive energy balance, lipogenic pathways are activated. These 
involve the esterification of free fatty acids into more complex lipids including 
triacylglycerides (TG), phospholipids and lipoproteins (18).  TGs comprise the 
common storage form of fatty acids, phospholipids are an integral component of 
cell membranes and lipoproteins have numerous and varied functions.  Central 
enzymes involved in lipid biosynthesis and esterification include fatty acid 
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synthase (Fasn) and glycerol-3-phosphate acyltransferases (Gpat)s (18).  Fasn 
also activates phospholipid synthesis in the ER (18).   
 
The liver converts excess dietary carbohydrates into fatty acids in a process 
known as de novo lipogenesis (14).  De novo lipogenesis comprises a series of 
cytosolic condensation reactions with the sequential addition of acetyl groups 
catalysed by acetyl-CoA carboxylase (Acc1).  In this way, a starting molecule 
(such as acetyl-CoA) is converted into malonyl-CoA, which can then undergo 
further elongation and esterification; Acc1 is the rate-limiting enzyme in this 
process (18). 
 
Under conditions of negative energy balance, fatty acids can be metabolised and 
utilised as a substrate for ATP generation through mitochondrial and 
peroxisomal beta-oxidation (18).  Fatty acid transport across the outer and inner 
mitochondrial membranes is facilitated by the carnitine palmitoyl transferases, 
Cpt-1 and Cpt-2, respectively (19).  Fatty-acyl-CoA undergoes initial 
dehydrogenation, donating electrons to cofactors that are then transferred to the 
electron transport chain (18).  In beta-oxidation, 2 carbon units are consecutively 
removed from fatty-acyl-CoA, resulting in either complete oxidation to acetyl-
CoA and CO2, or incomplete oxidation producing ketone bodies (19).  Acetyl-
CoA can then be further metabolized in the citric acid cycle.  
1.2.2 Transcriptional regulation of lipid homeostasis 
Energy homeostasis is controlled at a transcriptional level by a coordinated group 
of metabolic regulators.  These include members of the sterol regulatory 
element–binding protein family (e.g. Srebp-1a, Srebp-1c), peroxisome 
proliferator activated receptors (Pparα, Pparγ), adenosine monophosphate 
(AMP)-activated protein kinase (Ampk), Pparγ-coactivator 1 (Pparγc1), liver X 
receptor-like receptors (Lxrα, Fxr), CAAT/enhancer binding proteins (C/ebp), 
carbohydrate responsive element–binding protein family (Chrebp) and forkhead 
box protein 1 (Foxo1) (17, 18, 20).  The following section will provide an 
overview of these regulatory pathways, with particular attention to lipogenesis 
and lipid degradation. 
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Three Srebp isoforms (Srebp-1a, -1c and Srebp-2) are involved in regulating 
lipogenic pathways; these are produced as inactive precursors bound to the ER 
membrane (20).  When cellular levels of cholesterol are low, Srebp is escorted to 
the Golgi apparatus where it undergoes cleavage, releasing the active NH2-
terminal domain from the ER membrane (20).  This active domain subsequently 
translocates to the nucleus and induces the expression of numerous target genes 
via the sterol regulatory element (SRE) DNA binding domain (20).  Srebp target 
genes act to increase synthesis of fatty acids, triglycerides and cholesterol; 
significant lipogenic targets include Fasn, Acc1, ATP-citrate lyase (responsible 
for production of acetyl-CoA), Gpat and components of the fatty acid elongase 
complex (18, 20).  Srebp also induces genes involved in production of NADPH 
(reduced nicotinamide adenine dinucleotide phosphate) which is a cofactor 
required for a number of biosynthetic reactions (20). 
 
The Ppar family are ligand activated nuclear receptors that heterodimerise with 
retinoid X receptors (Rxrs) (21).  When activated by ligands and alongside co-
regulatory complexes, the heterodimer binds to the peroxisome proliferator 
response element (PPRE) DNA segment and regulates numerous metabolic 
genes (21).  The Ppar family proteins have active sensory sites and are activated 
by endogenous ligands, which may include fatty acids and fatty acid 
derivatives(19, 22).  Pparα is the most highly expressed Ppar isoform in the liver, 
and the principal role is to mobilise and degrade fatty acids through increased 
fatty acid oxidation (18). Pparα upregulates target genes that mobilise fatty acids, 
including Cpt-1, Cpt-2, Fabp and Fat/Cd36 (18, 19, 21). Pparα increases 
catabolism and acts to inhibit fatty acid biosynthetic pathways through the 
induction of malonyl-CoA decarboxylase, responsible for degradation of the 
fatty acid precursor malonyl-CoA(19).  Interestingly, Pparα may be 
preferentially activated by de novo and dietary derived ligands, rather than fatty 
acids mobilised from adipose tissue (19), although this remains unclear (22). 
Pparα also participates in apoprotein production and lipoprotein assembly (18, 
19, 21).   
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Pparγ is primarily expressed in adipose tissue; it is involved in adipocyte 
differentiation and acts to increase the expression of lipogenic enzymes including 
Fasn, Acc1, Fat/Cd36, Gpat and Fatp (18, 19).  Pparγ expression in the liver is 
believed to mediate metabolic coordination between hepatic and adipose tissue 
(19).  
   
Ampk is activated by an increasing ratio of AMP to ATP, allowing detection of 
cellular energy status (18).  When activated, Ampk stimulates numerous 
metabolic pathways to increase cellular energy including fatty acid oxidation and 
represses synthetic pathways, by down regulating Acc1 (18).  
 
Lxrα is a master regulator of cellular cholesterol flux, inducing genes involved in 
bile acid synthesis and excretion and dietary cholesterol absorption (18).  Lxrα 
also transcriptionally regulates Srebp-1c; sterols activate Lxrα which in turn 
induces Srebp-1c and promotes fatty acid synthesis (18).  Lxrα activation is 
competitively blocked by the presence of unsaturated fatty acids, therefore 
reducing Srebp-1c transcription; unsaturated fatty acids also accelerate the 
degradation of Srebp-1c mRNA (20).  Bile salts re-entering via the enterohepatic 
circulation in the fed state act as ligands to activate FXRs (22).  Activated Fxr 
appears to suppress lipogenesis, possibly by indirectly inhibiting Srebp-1c action 
(22).  Evidence suggests that Fxr down-regulates Pparα target genes and may 
reduce fatty acid oxidation, however it also may induce lipolytic hormones 
including fibroblast growth factor 21 (Fgf-21) (22).  This paradox suggests that 
Fxr may act in a modulatory capacity, differentially fine-tuning metabolic 
responses in fed and fasted states.   Ppars, Lxrs and Fxrs all act as heterodimers 
with Rxrs, therefore it is likely that competitive antagonism for Rxr binding is 
involved in maintaining coordinated and non-contradictory responses to cellular 
lipid homeostasis (18).  Energy homeostasis is also under hormonal control and 
is strongly influenced by the actions of hormones, insulin and glucagon secreted 
by the endocrine pancreatic, as well as by adipokines leptin and adiponectin from 
adipose tissue. 
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A simplified overview of regulatory lipid homeostasis pathways is given in 
Figure 1.2. A number of these regulators have been investigated as 
pharmacological targets for the treatment of metabolic disorders including 
dyslipidaemias, TIIDM and NASH. Ppar agonists include fibrate drugs acting on 
Pparα, used to treat hyperlipidaemias and thiazolidinediones that act on Pparγ 
are used in both TIIDM and NASH with fibrosis.  As described in Section 1.1.4 
above, Fxrs are potential therapeutic targets in NASH.  
 
 
Figure 1.2 Overview of regulation of lipid homeostasis pathways 
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1.3 OXIDATIVE STRESS 
1.3.1 Reactive oxygen species and cellular REDOX status 
Oxidative stress is described as the damage and stress response resulting from an 
imbalance favouring oxidation in the cellular reduction-oxidation (REDOX) 
status (23, 24).  The reactive oxygen species (ROS) superoxide anions (O2•-), 
hydrogen peroxide (H2O2) and hydroxyl radicals (HO•) can be endogenously 
produced during physiological reactions or be derived from exogenous sources 
(23). These molecules have the potential to induce irreversible damage through 
oxidation of cellular components including proteins, lipids and nucleic acids.  
However, ROS are also vital in the immune defence against pathogens and are 
involved in REDOX signalling pathways promoting cellular adaptation (23).   
 
The effects of ROS are variable depending on the amount and type of ROS 
produced as well as the subcellular localisation (23).  Partial reduction of oxygen 
during aerobic respiration can generate superoxide, which undergoes rapid 
conversion to H2O2 by superoxide dismutase (SOD) enzymes (23).  H2O2 is a less 
toxic ROS than superoxide and can be an important signalling molecule through 
regulated and reversible oxidation of cysteine thiol residues, induce 
conformational and functional protein alterations (23). Conversely, hydroxyl 
radicals are non-selective and toxic; mechanisms controlling iron homeostasis 
are particularly important to minimise the formation of these, which can be 
generated through the oxidation of ferrous ions (Fe2) (23).   
 
Oxidative stress can induce damage in numerous ways: Un-selective protein thiol 
oxidation can induce changes in protein structure and loss of function, lipid 
peroxidation can reduce the stability of phospholipid membranes, nucleic acid 
damage can introduce genomic instability and uncontrolled mitochondrial ROS 
can disrupt the respiratory chain (23, 24).  Oxidative stress has been the focus of 
research in numerous conditions such as normal ageing, cardiovascular disease, 
diabetes and NASH, (reviewed in (17, 25, 26)).     
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Cells have developed numerous mechanisms to maintain REDOX homeostasis 
and adapt to oxidative challenge.  These form a network of detoxifying 
enzymatic pathways and small antioxidant molecules that act in concert to 
neutralise or eliminate ROS.  Many components involved in the cellular response 
to endogenous and exogenous oxidative stress are controlled at a transcriptional 
level by the Nrf2/ARE pathway described in Section 1.4.  
1.3.2 Glutathione pathway 
An important component of the cellular response to ROS is glutathione (GSH), 
an intracellular tripeptide composed of glutamyl, cysteinyl and glycine residues, 
with an active thiol group (24).  GSH is involved in three general mechanisms of 
cellular antioxidant response: GSH can act directly as an electron donor; GSH 
can undergo conjugation with oxidised products and elimination; and GSH is a 
cofactor for antioxidant enzymes (24).  In its capacity as a direct antioxidant, 
GSH reacts with ROS, reactive nitrogen species or electrophiles, and is 
converted to the oxidised form glutathione disulphide (GSSG) as shown in 
Equation 1 (24).   
 
1) ROOH + 2GSH à ROH + GSSG + H2O 
 
The REDOX potential of a cell is often estimated from the ratio of GSH:GSSG 
(24).   This depends on dynamic factors such as ROS generation and the balance 
between GSH production, consumption, recycling and elimination (24).  GSH is 
produced in a two-stage process; the first step is peptide bond formation between 
glutamate and cysteine (24).  This is catalysed by the enzyme glutamate-cysteine 
ligase (Glc) and is the rate-limiting step in biosynthesis (24).  GSSG can be 
restored to GSH by the enzyme glutathione reductase (Gsr) with the cofactor 
NADPH, as shown in Equation 2 (24).     
 
2) GSSG + NADPH + H+ à 2GSH + NADP+ 
 
GSH is synthesised in the cytosol and then distributed and maintained in 
relatively discrete pools in the cytosol, mitochondria, ER and nuclear 
compartments where it has organelle-specific functions (24).  There has been 
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much interest in the mitochondrial GSH pool due to production of ROS 
associated with mitochondrial respiration.  The role of GSH and GSSG in the ER 
is discussed further in Section1.5. 
 
GSH is a cofactor in reactions catalysed by the glutathione peroxidase (Gpx) 
family of enzymes that reduce H2O2 and organic peroxides of free-fatty acids, 
cholesterols and phospholipids (24).  Conjugation of GSH to electrophilic 
compounds is facilitated by a number of glutathione S-transferase (Gst) isoforms.  
The GSH-conjugate products are typically excreted or partially recycled (24).  
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1.4 NUCLEAR RECEPTOR (ERYTHROID-DERIVED 2)-LIKE 2 (NRF2) 
1.4.1 The Nrf2/Antioxidant Response Element pathway 
Nuclear receptor (erythroid-derived 2)-like 2 Nrf2 belongs to the Cap’n’Collar, 
basic leucine zipper family of transcription factors (27).   Nrf2 is a master 
regulator that orchestrates the intracellular response to oxidative stress as well as 
activating transcription of over 250 genes targets, involved in diverse cellular 
functions including cytoprotection, antioxidant response, detoxification, and lipid 
and carbohydrate metabolism (27).  
 
The common DNA binding region known as the antioxidant response element 
(ARE) (also known as the electrophile response element (EpRE)) was identified 
and characterised by Rushmore and colleagues in a series of studies in the early 
1990s(28-30).  The ARE is a highly conserved, cis-acting DNA motif found in 
the promoter region of many genes, including phase II metabolism enzymes (31).  
Itoh et al examined Nrf2 as a possible candidate to bind the ARE motif after 
identifying consensus sequence similarity (31).  Through the generation of Nrf2-
null mice, the study found that Nrf2 acts as an obligatory heterodimer with 
small-Maf proteins and is able to bind numerous ARE promoter sequences, 
demonstrating a common mechanism of phase II enzyme induction (31). 
 
In association with regulatory cofactors, the Nrf2/sMaf heterodimer is able to 
induce the transcription of numerous target genes via the ARE promoter region.  
Canonical genes regulated by Nrf2 include major detoxification enzymes 
NAD(P)H quinone dehydrogenase 1 (Nqo1) and haem-oxygenase 1 (Hmox1), as 
well enzymes involved in the glutathione pathway, including the modifier 
(Gclm) and catalytic (Gclc) subunits of Gcl (the rate-limiting enzyme in 
glutathione synthesis) (27).  
1.4.2 Nrf2-Keap1 association 
Nrf2 is constitutively expressed; under basal conditions, it is sequestered in the 
cytoplasmic compartment in association with Kelch like-ECH-associated protein 
1 (Keap1) via two binding sites in the Nrf2 Neh2 domain (32). Keap1 is a 
cysteine rich dimeric substrate adaptor protein that both anchors Nrf2 and 
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interacts with a cullin-3 RINGbox1 E3 ubiquitin ligase complex (27).  This 
facilitates the continuous polyubiquitination and proteasomal degradation of 
Nrf2 by the Keap1-Cullin3-E3 ubiquitin ligase complex, maintaining Nrf2 at low 
levels (27). 
 
Keap1 has many reactive cysteine residues, which induce a conformational 
change in the presence of oxidative and electrophilic species, allowing cells to 
sense alterations in intracellular redox status and respond to a variety of stimuli.  
The exact mechanism is not yet completely understood; early theories involve a 
hinge-and-latch mechanism, whereby ROS induce a conformational change in 
Keap1 resulting in the release of Nrf2 (33). However, recent evidence suggests 
that ROS activation of Keap1 leads to strengthened Nrf2 binding but a reduced 
ability of Keap1 to interact with the degradation complex (27).  Thus, Keap1 
would remain bound to non-degraded Nrf2 and newly synthesised Nrf2 would 
circumvent sequestration and degradation (27).  Therefore, under conditions of 
oxidative stress Nrf2 is able to translocate to the nucleus, heterodimerise in 
complex with small maf proteins and activate transcription through the ARE. 
 
Nrf2 is also under a further post-translational regulation through an independent 
mechanism involving glycogen synthase kinase 3 (Gsk-3) and the Skp1-Cul1-F-
box ubiquitin ligase (SCF/βTrCP) complex (34).  Gsk-3 phosphorylates residues 
within the Neh6 domain of Nrf2, enhancing association of βTrCP and promoting 
SCF/βTrCP dependent degradation (34). 
 
1.4.3 Nrf2 in health and disease 
There has been much research into Nrf2, as Nrf2 may confer a cellular survival 
advantage against oxidative insult that can be physiologically adaptive in normal 
cells.  Due to this cellular protective role, suppression or ineffective Nrf2 could 
be a factor in inflammatory conditions resulting in cellular damage. However, 
constitutive activation, whether by Keap1 deletion or Nrf2 amplification, can 
also promote survival in pathological cells and up-regulation has been observed 
in a number of cancer lines (35).  Uninhibited Nrf2 activity in tumour cells via 
loss of Keap1 can promote resistance to ROS inducing chemotherapeutic agents 
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(35).  There is therefore a delicate balance between cellular survival, protection 
and tumorigenesis.  Although it is known that Nrf2 has a key role in cellular 
defence against oxidative stress, the role of Nrf2 in different environments of 
cellular stress has not been fully explored.  Nrf2 may be of particular importance 
in NAFLD: Nrf2 knockdown mice are known to be more susceptible to NASH 
(36, 37) and there is evidence demonstrating activation of the Nrf2/ARE pathway 
in the human disease, discussed further below.   
1.4.4 Nrf2 in human NAFLD 
Hardwick et al (2010) investigated the expression and activity levels of selected 
proteins induced by NRF2 in a total of 54 human liver samples (38).  The tissue 
was scored using the NAS, histologically evaluated and categorised according to 
disease severity: Normal (n=20), steatotic (n=12), NASH and fatty (n=11) and 
NASH not fatty (n=11).  Steatosis was determined by fatty infiltration of >10%, 
NASH (fatty) was categorised by the presence of macrovesicular fatty deposits 
and inflammation, and NASH (not fatty) samples demonstrated more severe 
inflammation and fatty infiltration of <5%.  
 
GSH and TBARS (thiobarbituric acid- reactive substances) assays were used to 
assess cellular oxidative stress: Concentrations of GSH and GSSG as well as the 
GSH:GSSG ratio were found to be significantly decreased with progressive 
disease severity (38). TBARS assay demonstrated that malondialdehyde (MDA), 
produced by lipid peroxidation, also significantly increased with disease 
progression.  This provides direct evidence that hepatocytes are subject to 
oxidative stress and lipid peroxidation in human NAFLD (38). 
 
The expression and activity levels of NQO1, GST and GCL were assessed using 
a range of real-time, reverse transcriptase polymerase chain reaction (rtPCR), 
immunoblotting and enzyme activity assays.  Results showed that NQO1 mRNA 
and relative cytosolic protein levels significantly increased with severity and 
progression of NAFLD (38).  Furthermore, NQO1 enzymatic activity also 
increased with disease progression.  GCLM mRNA showed an increasing trend 
but did not reach significance, and protein levels were unchanged.  The mRNA 
expression of GST isoforms (A1, A2, A4, M3 and P1), and protein levels of GST 
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A and GST P were increased with disease progression. The enzymatic activity of 
GST showed decreasing activity with disease severity, which persisted even in 
the presence of supplemented GSH levels (38).    
 
The study stained liver samples for NRF2 and the percentage nuclear 
translocation was averaged for each group: Immunohistochemistry demonstrated 
an average NRF2 nuclear translocation of ~2% of hepatocytes in normal liver 
samples (38).  This was increased in the NAFLD groups, with nuclear 
translocation in an average of 25%, 23% and 22% of hepatocytes for steatotic, 
NASH (fatty) and NASH (not fatty) groups, respectively (38). 
 
Taken together, these results demonstrate increasing levels of lipid peroxidation 
and oxidative stress as disease severity increases, alongside the nuclear 
translocation of NRF2 and induction of classical gene targets, NQO1 and GST.  
Although mRNA levels of certain GST isoforms were increased other isoforms 
(M1, M2 and M4) were not significantly different, and GST M protein levels 
were reduced.  The authors suggest differential regulation of GST isoforms, and 
postulate that increased expression of GST P may indicate predisposition to 
fibrosis and HCC, noting that further study is required (38).  
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1.5 ENDOPLASMIC RETICULUM STRESS 
1.5.1 The function of the endoplasmic reticulum (ER)  
The endoplasmic reticulum (ER) is a specialised membranous organelle that 
extends from the outer nuclear membrane; it is subdivided functionally and 
structurally into the nuclear envelope, rough (RER) and smooth (SER) domains 
(39, 40).  The RER and SER can be distinguished morphologically through 
association of the RER with ribosomal units, but also more importantly, by 
differences in membrane protein composition (39). Functions of the ER include 
the post-translational modification of newly synthesised proteins, detoxification 
and the biosynthesis of phospholipids and steroids (39, 40).  Cells that have high 
levels of protein production, such as plasma cells that produce and secrete 
immunoglobulins have abundant ER. The ER lumen also comprises the major 
intracellular site of calcium storage, and the ER (and the specialised 
sarcoplasmic reticulum in myocytes) is highly involved in calcium homeostasis 
(39, 41). 
1.5.1.1 Protein folding  
Nascent proteins are released from ribosomes and transported across the ER 
membrane into the ER lumen.  These mature as they traverse along the ER, 
undergoing modifications including folding, glycosylation, formation of tertiary 
protein structure and multiple subunit assembly (41).  Mature proteins exit the 
ER and those destined for secretion or insertion into the plasma membrane are 
packaged in the Golgi apparatus (11).    
1.5.1.2 ER REDOX status 
Protein folding requires oxidation and disulphide bond formation so the ER 
lumen has a specialised REDOX environment to enable this (24, 42). Disulphide 
bond formation is catalysed by ER resident proteins, including protein disulphide 
isomerise (Pdi) and endoplasmic reticulum oxidoreductin 1α (Ero1α): 
Polypeptide chains are oxidised by Pdi, which subsequently undergoes oxidation 
by Ero1α in the presence of the co-substrate FAD (flavin adenine dinucleotide) 
(42).  Ero1α re-enters this cycle following oxidation by molecular O2 (42).  The 
ER maintains a more oxidised environment than other subcellular compartments 
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as demonstrated by the GSH:GSSG ratio; in the ER the proportion of the 
oxidised form reaches up to 25% of total, compared to the cytosol where it 
typically comprises less than 1% (24).    
1.5.1.3 Lipid and steroid biosynthesis 
The ER is works in close concert with the Golgi complex and together these 
comprise the endomembranous compartment and are major sites of phospholipid 
synthesis (40).  Phospholipids are integral cell membrane components and the 
most abundant of these are synthesised in the ER and Golgi organelles.  Many 
enzymes involved in lipid biosynthetic pathways are associated with the ER, 
including acyltransferases such as Gpat (40), and lipid components of 
lipoproteins are also synthesised in the ER(18). 
1.5.2 ER stress and the unfolded protein response (UPR) 
Protein folding is a complex process in which errors can arise; cells have highly 
conserved mechanisms for the detection and resolution of such errors (41, 43-45).  
ER resident proteins are involved in pathways that maintain ER homeostasis, 
balancing the ER processing capacity to accommodate cellular protein 
requirements (41, 43-45). ER stress occurs when the capacity of the ER is 
overwhelmed, misfolded and unfolded proteins accumulate and the normal 
trafficking of proteins through the ER is disrupted (41, 43-45). ER stress 
stimulates an adaptive signalling network known as the unfolded protein 
response (UPR), which has been reviewed extensively (41, 43-46).  
Complimentary signalling pathways of the UPR act in concert to increase the 
capacity of the ER, reduce protein demand, and increase degradation of 
misfolded products (41, 43-45).   
 
The UPR acts at a transcriptional level to down-regulate non-essential proteins 
while preferentially inducing cell survival proteins and upregulating ER 
chaperones and enzymes (41, 43-45).  The UPR increases ER associated 
degradation (ERAD), stimulates phospholipid synthesis to lengthen the ER 
membrane (40) and slows the trafficking of proteins through the ER (43).  The 
UPR is an adaptive mechanism that acts to attenuate and resolve ER stress, 
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however if homeostasis cannot be restored and chronic ER stress persists, the 
UPR ultimately activates proapoptotic pathways (41, 43). 
1.5.3 Pathways of the UPR  
The UPR is classically described as three complimentary signalling pathways, 
each of these relating to one of three proximal ER stress sensing transmembrane 
proteins; Inositol-requiring enzyme 1 (Ire1), protein kinase RNA-like 
endoplasmic reticulum kinase (Perk) and activating transcription factor 6 (Atf6) 
(41, 43-45).  An overview of these pathways is described below and then 
depicted in Figure 1.3.  Under non-stressed conditions, the ER chaperone binding 
immunoglobulin protein (Bip) moderates the activity of these proteins by binding 
to the luminal sensory domain, maintaining an inactive state (47).  When 
unfolded proteins accumulate, Bip dissociates, promoting further signal 
transduction.  This mechanism allows for a regulated, adaptive response to 
evolving conditions within the ER environment (47).  
1.5.3.1 Ire1α and Xbp1 
The transmembrane serine/threonine protein kinase Ire1 was the first identified 
ER stress sensor; initially discovered by Nikawa and Yamashita (48), the role of 
this protein in response to ER stress was characterised in yeast by Cox and 
colleagues in the Walter lab (49). The mammalian homologue, Ire1α, is 
ubiquitously expressed, particularly in the pancreas, and is preferentially 
localised to the nuclear membrane (50).   
 
The N-terminal domain of Ire1α in the ER lumen detects perturbations in protein 
folding with fragments of unfolded polypeptide chains acting as ligands to 
activate Ire1 (42, 51, 52).  Bip modulates activity by associating with Ire1α and 
reducing sensitivity in low ER stress environments, and also contributes to 
deactivation following by associating with Ire1α following the attenuation of ER 
stress (42). 
 
Under conditions of ER stress, Ire1α undergoes oligomerization and trans-
autophosphorylation of serine residues, resulting in the activation of a 
cytoplasmic endoribonuclease domain (53-55).   Activated Ire1α has RNase 
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activity and directly cleaves an intron from the mRNA of X-box binding protein 
1 (Xbp1) through an unconventional splicing mechanism, independently of the 
spliceosome; this is phylogenetically conserved between the mammalian Xbp1 
and yeast homologue (Hac1) (53, 56, 57).  Splicing of Xbp1 by Ire1α removes a 
26-nucleotide intron, causing frameshift and the production of a larger and more 
stable protein, Xbp1-spliced (Xbp1-s) (53).  There is some evidence that 
induction of Ire1α downstream targets requires cooperative activation of the Atf6 
branch of the UPR to provide newly transcribed mRNA of Xbp1-unspliced 
(Xbp1-u) (53), however this has not been definitively proven (58).   
 
The nuclease activity of Ire1α also increases the degradation of mRNAs in 
response to ER stress, possibly through direct cleavage (59). This reduces ER 
input in a process known as regulated Ire1α dependent decay (RIDD) (59). 
 
The product Xbp1-s is a Cre-binding protein/Activating transcription factor 
(Creb/Atf) that translocates to the nucleus and induces the expression of UPR 
target genes such as components of ERAD machinery and ER chaperones, 
through the promoter UPR element (53, 58).  Some evidence suggests that Xbp1-
s specific targets include the DnaJ-like accessory proteins Dnajb9, Dnajb11 and 
p58IPK, that act to augment chaperone activities, and Edem (ER degradation 
enhancing α-mannosidase-like protein), which participates in ERAD (58).  
Xbp1-s also has some autoregulatory activity and potentially cross-regulates Atf6 
(58).   
 
Xbp1 is essential for hepatocyte growth; the knockout of this gene is 
embryonically lethal in mice due to hepatic hypoplasia (60).  Xbp1-s also 
induces the expression of many non-UPR target genes such as α-fetoprotein and 
α1-antitrypsin (60).  Other targets are involved in lipid and glucose metabolism 
(61).  For example, Xbp1-s is able to induce lipogenic genes independently of 
Srebp-1c, and in the fasted state upregulates the expression of Pparα (61).   
1.5.3.2 Perk and Eif2α 
Perk is another transmembrane kinase that undergoes oligomerization and trans-
autophosphorylation: Phosphorylated (phospho)-Perk has kinase activity that 
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subsequently phosphorylates eukaryotic initiation factor 2α (Eif2α). Phospho-
Eif2α then acts to selectively inhibit translation, thereby controlling and reducing 
input into ER (41).  Phospho-Eif2α also activates the downstream effector, Atf4, 
which induces targets including stanniocalcin 2 (Stc2) (involved in regulating 
Ca2+ homeostasis (62)), Atf3, c/ebp homologous protein (Chop), and growth 
arrest and DNA damage-inducible protein 34 (Gadd 34) (45).  The latter of these 
are involved in promotion of proapoptotic pathways. 
1.5.3.3 Atf6 
Atf6 is an integral ER transmembrane glycoprotein that is constitutively 
expressed as a 90kDa protein (63).  ER stress causes Atf6 to undergo cleavage by 
Site-1 and Site-2 proteases in the Golgi apparatus (64).  The cytosolic N-terminal 
of Atf6 that contains a basic-leucine zipper motif is released as a 50kDa fragment 
and translocates to the nucleus, where it is acts as a transcription factor (63).  
Atf6 potentially induces the expression of UPR target genes including Xbp1-u, 
thereby acting in concert with activated Ire1α by providing the substrate for 
splicing (53).  
 
 
Figure 1.3 Simplified overview of UPR sensor pathways, adapted from (44) 
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1.5.3.4 Cell fate decisions 
It has been well characterised that the Perk arm of the UPR can stimulate 
proapoptotic pathways under conditions of chronic ER stress (65).  The Ire1α 
branch of the UPR is also able to interact with proapoptotic pathways through the 
association of Tnf receptor associated factor (Traf), leading to downstream 
phosphorylation of Jun-amino-terminal kinase (Jnk) (44, 66).  Further 
identification small molecules that have the potential to preferentially induce 
distinct branches of the UPR may provide more insight into the contributions of 
each UPR pathway in response to ER stress (67). 
 
1.5.4 ER stress in disease 
ER stress is known to contribute to many pathological conditions, particularly 
conditions where either cellular protein production is increased or dysfunctional, 
including viral, neurodegenerative processes, α1-antitrypsin disorder, retinitis 
pigmentosa and amyloidoses (45, 67).  ER stress has also been reported to 
contribute to micro-vascular complications of hyperglycaemia in diabetes 
mellitus independently of oxidative stress (68).  The role of ER stress in liver 
disease and metabolic disorders has been a subject of much interest in recent 
years (reviewed in (44, 47, 69)).   The ER is more abundant in secretory cells 
with high levels of protein production; hepatocytes are the primary site of 
synthesis of many proteins including plasma proteins, clotting factors, 
complement cascade and acute phase proteins; it is therefore possible that ER 
stress contributes to the development and pathogenesis of NASH.  Interestingly, 
there is growing evidence that saturated fatty acids induce ER stress in vitro, 
providing a potential mechanism by which steatotic hepatocytes may be subject 
to ER stress.   
1.5.5 ER stress in human NAFLD 
The expression and regulation of the ER stress response in human NAFLD has 
been investigated (70). Protein expression was assessed in 27 liver samples, 
separated into four groups as described above: Normal (n=7), steatotic (n=7), 
NASH and fatty (n=8) and NASH not fatty (n=5).  Western blotting 
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demonstrated significantly increased levels of XBP1-s in NASH groups 
compared to control and levels of STC2 were significantly increased in the 
NASH (not fatty group) (70). Although strong expression changes were observed 
for ATF4 and CHOP in tissue from some NAFLD patients, results did not reach 
significance due to large variation (70).  The ratios of phosphorylated to total 
protein for either EIF2α or JNK were not significantly different between groups 
(70).  XBP1 immunohistochemistry demonstrated increased nuclear staining in 
steatosis compared to control, which was more prominent in NASH groups (70).  
Using gene set enrichment on 45 samples (divided into groups of normal, 
steatosis and NASH), the study found that both the ER stress/UPR and 
lipogenesis pathways were down regulated, whereas apoptosis and autophagy 
were upregulated in NASH compared to control (70).  Autophagy was also 
upregulated in steatosis compared to control, which may be an adaptive response 
to lipotoxicity (70). 
 
Microarray gene expression of ER stress/UPR components demonstrated 
significant reduced levels of ATF4 and XBP1 mRNA in NASH compared to 
control and steatosis groups (70).  ATF6 mRNA was found to be increased in 
steatosis compared to control, but not in NASH. Levels of IRE1, PERK and JNK 
mRNA were not significantly different between groups.  Levels of STC2 were 
increased, and EIF2α and CHOP mRNA were decreased in NASH compared to 
steatosis but not significantly different from control (70).  Although protein 
levels of some ER stress markers were significantly increased, gene set analysis 
of the ER stress/UPR pathway demonstrated a pattern of transcriptional down 
regulation in NASH (70).  The authors also suggest a negative feedback 
mechanism to explain the finding (70), which requires further investigation.  
Particularly, XBP1 mRNA was significantly reduced in NASH, whereas protein 
levels and nuclear staining were significantly increased; as the authors propose, 
an increase in the proportion of XBP1-s mRNA was not assessed and could 
account for this finding (70).  
 
Puri et al 2008 evaluated the expression of ER stress markers in human NAFLD 
and tested the hypothesis that the UPR would increase with disease progression 
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(71).  The study utilised liver biopsy specimens from patients with metabolic 
syndrome alone (control group; n=17), metabolic syndrome with steatosis (n=21) 
and metabolic syndrome with NASH (n=21), excluding any patients with 
evidence of bridging fibrosis or cirrhosis.  Metabolic syndrome was evaluated 
using Adult Treatment III criteria of abdominal obesity, hypertriglyceridaemia, 
lowered levels of high-density lipoprotein cholesterol, hypertension and impaired 
fasting glucose (72).  NAFLD was diagnosed clinically as the elevation of 
enzymes or ultrasound evidence of fatty liver with exclusion of other aetiologies, 
including alcohol; these were assessed histologically and separated into steatosis 
and NASH groups.  Histological parameters were qualitatively assessed and 
samples were scored quantitatively using the NAS. The study assessed 
expression of classical UPR pathway components: EIF2α, ATF4, XBP1, BIP, 
EDEM, CHOP and GADD34 (72).  Apoptosis was investigated by assessing 
expression of classical pathway components, phospho-JNK and p38 mitogen-
activated protein kinase (MAPK), alongside TUNEL (terminal deoxynucleotidyl 
Transferase dUTP Nick-End Labeling) assay.  TUNEL assay is used to identify 
apoptotic cells through detection of nicks, damage and fragmentation of double-
stranded DNA (73).   
 
Results demonstrated that phospho-EIF2α was significantly increased in patients 
with NAFLD compared to metabolic syndrome alone (72).  However, levels of 
downstream targets - ATF4 (mRNA and protein), CHOP and GADD34 (both 
mRNA) were not significantly different between groups or control (72). Levels 
of XBP1-u mRNA and protein were increased in patients with steatosis 
compared to control; there was also trend of increased XBP1-u mRNA in NASH 
compared to steatosis, however this did not reach statistical significance (72).  
XBP1-s mRNA was not different between groups, despite findings of individual 
NAFLD patients with highly increased levels, however this was found to directly 
correlate with histological severity (assessed by NAS) (72).  Interestingly, 
XBP1-s protein expression was significantly reduced in NASH (72).  A trend of 
increasing EDEM mRNA was also noted with disease progression.  BIP mRNA 
was increased in NASH compared to the steatosis group, but was not 
significantly different from control.  Levels of phospho-JNK were significantly 
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increased in NASH alone, p38 MAPK activity was increased in both steatosis 
and NASH groups compared to control and TUNEL assay also demonstrated an 
increasing apoptotic activity in steatosis and NASH (72).   
 
These results demonstrate the complexity and variability of the human disease, 
but indicate the potential role of ER stress in human NAFLD.   
1.5.6 ER stress and fatty acids 
Wang et al 2006 investigated the effects of different dietary components used to 
induce hepatic steatosis in rats (74).  The group compared the effects of three 
diets, rich in sucrose, saturated fatty acids (SFA; lard), and polyunsaturated fatty 
acids (PUFA; corn oil) respectively, against control diet in rats for up to 24 
weeks.  The study assessed lipid levels, responses to insulin challenge and 
mitochondrial integrity as well as hepatic expression of ER stress markers Bip, 
Chop and Xbp1-s.  Rats were also challenged with partial hepatectomy and 
lipopolysaccharide (LPS) isolated from Escherichia coli. 
 
Results demonstrated significantly increased hepatic triglycerides in all three 
dietary groups compared to control, with SFA and sucrose diets displaying 
higher levels than the PUFA group (74).  Fat mass was significantly increased in 
the SFA and PUFA diets at 24 weeks.  Despite basal similarity in glucose and 
insulin levels, the three experimental diet groups showed significantly reduced 
response to insulin during euglycaemic hyperinsulinaemic clamp studies (74).  
Mitochondrial integrity, assessed by JC-1 fluorescence (a dye that detects 
alterations in mitochondrial membrane potential), was reduced at 4 and 24 weeks 
by all diets compared to control; for both insulin response and mitochondrial 
integrity, no differences were noted between the three diets investigated (74).     
 
Hepatic levels of Xbp1-s, Bip and Chop in were significantly increased by the 
sucrose and SFA diets (74).  Caspase-3 activity was also increased in these two 
groups compared to control and PUFA diets, and these results were supported by 
isolated hepatocyte studies.  After 1 week of respective diets, rats underwent 
partial hepatectomy. Following this, liver weight recovery was delayed in the 
three diet groups compared to control, and to a greater extent in the SFA group 
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and sucrose fed rats, supported by estimates of cell proliferation (74).  Serum 
levels of AST and ALT were used to assess the response to LPS; enzymes were 
significantly more increased in SFA fed groups, and were also increased basally 
in these two diet groups (74).  These results demonstrate that ER stress is 
increased in models of steatosis induced by both a sucrose rich diet and by diet 
rich in SFA (74).  The same dietary groups that had increased ER stress markers 
also showed less capacity to respond to further insult in the form of partial 
hepatectomy.   
 
The same group examined the effects of selected SFA and unsaturated fatty acids 
on ER homeostasis in vitro (75).  Using a rat hepatoma cell line, Wei et al 
showed that ER stress was induced by incubation with the SFA palmitate or 
stearate, but not by the unsaturated fatty acids oleic acid or linoleic acid (75).  
The study utilised known pharmacological ER inducers thapsigargin and 
tunicamycin as positive control treatments. 
 
Treatment for 6 hours with palmitate or stearate induced phosphorylation of 
Ire1α and Xbp1-splicing, and Eif2α phosphorylation was stimulated in a time 
dependent manner, in keeping with positive control cells.  Saturated fatty acid 
treatment also increased mRNA of the ER stress markers Atf4, Chop, Bip and 
Gadd34; this differed from thapsigargin and tunicamycin treatments, which 
induced a larger range of ER stress markers.  Cells incubated in either of the 
unsaturated fatty acids investigated, or thapsigargin, demonstrated increased 
caspase activity at 6hours; DNA laddering (a marker of apoptosis) and reduced 
cell viability was observed at 16hours.  Co-treatment with the caspase inhibitor 
prevented these effects, but did not have any significant effect on the induction 
of ER stress markers.   
 
Cellular concentrations of ceramide were increased with saturated fatty acid 
incubations, so a known inhibitor of ceramide synthetase (fumonisin B1) was 
used to test whether the observed induction of ER stress markers was a result of 
ceramide production.  Although the inhibitor prevented increases in ceramide 
concentration, this did not have significant effect on ER stress markers or DNA 
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laddering.  This indicates that ER stress induction and apoptosis occurred 
independently of ceramide.  
 
No increase in markers of ER stress, apoptosis or cell viability were observed 
with either of the unsaturated fatty acids tested.  In fact, addition and titration of 
oleic acid or linoleic acid was able to attenuate or prevent increases in mRNA 
and DNA laddering induced by palmitate.  This study provides further evidence 
of a correlation between saturated fatty acids and induction of ER stress, and also 
demonstrates the potential importance of dietary saturated and unsaturated fatty 
acid composition in human NAFLD.  From the data of mRNA induced by 
saturated fatty acids (particularly Atf4, Chop and Gadd34), it is possible that the 
unsaturated fatty acids palmitate and stearate may induce the PERK arm 
preferentially over other UPR pathways. 
 
Palmitate has also been shown to induce lipid accumulation, ER stress, apoptosis 
and cell death in cardiomyocytes in vitro (76).  In keeping with other studies, 
these effects were completely ameliorated by co-administration of oleate.    ER 
stress markers were increased in a dose and time dependent manner by palmitate: 
Interestingly, Bip mRNA levels were significantly increased but Bip protein 
levels where only marginally elevated by palmitate.  The authors tested the 
hypothesis that palmitate induced Bip degradation through proteasomal 
ubiquitination, by blotting for ubiquitin in Bip immuno-precipitates.  The study 
demonstrated that the ubiquitin signal in isolates from palmitate treated cells was 
significantly increased compared to isolates from both positive (tunicamycin 
treated) and untreated control cells. This finding suggests that Bip may be under 
post-transcriptional regulation through the ubiquitin-proteasome pathway. 
 
Interestingly, the study by Haffar et al demonstrated distinct staining patterns 
between cells treated with palmitate, compared to oleate and bovine serum 
albumin (BSA)-control cells (76).  Although total levels of fatty acid uptake and 
total TG content were confirmed to be similar, oleate resulted in small, bright 
spherical pattern of lipid staining, described as consistent with droplet 
morphology, whereas palmitate staining was characteristically diffuse and faint, 
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with some spherical morphology but also demonstrate numerous non-spherical 
and irregular objects.  Due to the nature of the staining, the authors suggest that 
palmitate may accumulate in the ER, potentially disrupting ER homeostasis 
through direct lipotoxicity.  This requires further confirmation, but could explain 
the mechanism by which ER stress is caused by palmitate.  Cardiovascular 
mortality and morbidity is increased in NAFLD and TIIDM, and TIIDM is also 
associated with steatotic cardiomyopathy.  It is therefore possible that a common 
mechanism of ER stress induced by palmitate lipotoxicity may take place in the 
liver and cardiac tissue of patients with features of the metabolic syndrome.   
 
Pharmacological induction of ER stress causes hepatic steatosis in rodent models 
(77, 78). Rutkowski et al investigated the relationship between ER stress and 
metabolism by assessing the effect of ER stress on mice deficient in distinct 
components of the UPR (78).  Results showed that following tunicamycin 
challenge, Atf6α-null mice, p58IPK-null mice, mice with liver specific Ire1α 
deletion and Eif2-mutant mice all developed hepatic steatosis.  While wild type 
(WT) counterparts were able to resolve ER stress, these deficient mice all 
developed persistent UPR activation, demonstrated by upregulation and nuclear 
localisation of Chop at 48hours (78).     
 
In response to tunicamycin, the livers of Atf6α-null mice showed microvesicular 
steatosis and an increased loss of structural ER integrity compared to WT mice.  
Atf6α-null mice also developed other features of metabolic disturbance, 
becoming hypoglycaemic and more severely insulin resistant than WT mice.  
Atf6-null mice also demonstrated increased reductions in serum levels of low 
and very low density lipoprotein (LDL and VLDL, respectively) following 
tunicamycin treatment, compared to WT mice (78). 
 
Microarray profiling demonstrated similarity in basal gene expressions between 
WT and Atf6α-null mice (78).  Tunicamycin challenge resulted in the 
transcriptional upregulation of numerous ER stress markers in WT mice, some of 
which were attenuated in Atf6-nulls (specifically Edem, Pdi family members 
PdiA4 and PdiA2, and co-chaperones p58IPK and Endoplasmin). However, in 
 44 
both WT and Atf6-null mice, tunicamycin treatment resulted in the suppression 
of a number genes involved in metabolism and lipid homeostasis, including 
Srebp1, C/ebp, Pparα, Pparγc1, Foxo1, microsomal triglyceride transfer protein 
(Mttp), Fasn and fatty acid desaturase enzymes (78).  Furthermore, while these 
changes were attenuated by 48hrs in WT mice, mice lacking UPR components 
demonstrated continued suppression of a number of metabolic transcriptional 
regulators including Srebp1, C/ebpa, Pparα, Pparγc1 and Chrebp (78).  
Expression of transcriptional target genes involved in fatty acid oxidation, 
lipogenesis, gluconeogenesis and lipoprotein synthesis pathways were also 
reduced (78).  The authors suggest from the pathways inhibited that the 
accumulation of hepatic TG may result from reduced fatty acid oxidation rather 
than increased lipogenesis or uptake, although this warrants further investigation 
(78).   
 
Similar patterns of gene suppression were found in p58IPK-null, Ire1α-null and 
Eif2-mutant mice, leading the authors to conclude that metabolic dysfunction 
was due to ER stress rather than any specific pathway of the UPR (78).  The 
study showed in vitro that levels of C/ebp were significantly reduced by 
actinomycin D (a translational inhibitor), indicative of a pattern of constitutive 
expression and basal degradation; therefore suppression under conditions of ER 
stress would result from inhibition of synthesis rather than increased degradation 
(78).  The study assessed the response of Chop-null mice to tunicamycin and 
found that Chop-null mice had less hepatic lipid accumulation and suppression of 
metabolic regulators was attenuated. Therefore it is possible that Chop acts to 
suppress other C/ebp family members following ER stress (78) . The study 
concluded that suppression of metabolic genes is directly related to the hepatic 
ER stress response, and that metabolic dysfunction is perpetuated in conditions 
of unresolved ER stress (78).   
 
 Jo et al found that hepatic mRNA expression of ER stress markers (Bip, Chop, 
Dnajb9, Xbp1-s) were significantly induced alongside steatosis by tunicamycin 
in a mouse model (77).  Expression of ER stress markers was not increased in 
adipose tissue.  The study investigated the potential roles of lipogenesis, fatty 
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acid oxidation and lipid in a mouse model of pharmacological induced ER stress 
and steatosis.  Results demonstrated suppression of the lipogenic genes Srebp-1c, 
Fasn and stearoyl-CoA desaturase 1 (Scd1) in the liver and expression of genes 
involved in fatty acid oxidation was not consistently different.  Lipid delivery 
genes also showed a mixed pattern, however levels of hepatic VLDL receptor 
(VLDLR) mRNA were significantly increased.  Expression of VLDLR was 
induced by tunicamycin in primary hepatocytes and MEFs, but not in two 
adipocyte cell lines (77).  
 
In primary hepatocytes, actinomycin D (an antibiotic agent that acts as a 
transcriptional inhibitor) was able to repress both ER-stress induced triglyceride 
accumulation and expression of VLDLR, Bip and Dnajb9 (77).  Treatment with 
cycloheximide, a protein synthesis inhibitor, was also able to repress 
pharmacological ER stress mediated TG accumulation in vitro.  The authors 
suggest these results demonstrate 1) that transcriptional upregulation of VLDLR, 
and 2) newly synthesised proteins, respectively, are required for tunicamycin 
induced triglyceride accumulation (77).  However, the strong possibility that 
both actinomycin and cycloheximide are acting to alleviate ER stress, via 
reduction of transcriptional demand and input into the ER or by alternative 
pathways must also be considered.  
 
Interestingly, suppression of VLDLR via small interfering RNA (siRNA) or in 
primary hepatocytes from VLDLR-deficient mice was able to alleviate 
intracellular triglyceride accumulation, supporting the potential role of VLDLR 
in steatosis (77). The study demonstrated that suppression of the Perk pathway 
(rather than Ire1α or Atf6 arms of the UPR) attenuated VLDLR expression 
induced by ER stress in murine epithelial fibroblasts and primary hepatocytes 
(77).  Furthermore, overexpression of Atf4 increased VLDLR expression.  This 
suggests possible cross-talk between the Perk arm of the UPR and lipid delivery 
pathways, supported by the presence of two conserved Atf4 binding motifs in the 
promoter region of the murine VLDLR gene (77). 
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The effects of tunicamycin treatment were assessed in VLDLR-deficient mice; 
although mRNA expression of ER stress markers was comparable to WT, 
hepatic triglyceride in VLDLR-deficient mice increased to a significantly lesser 
extent (77).  Similarly, when fed a high fat diet VLDLR-deficient mice 
accumulated less hepatic triglyceride than wild type counterparts.  Results from 
an in vivo detergent assay showed suppression of VLDL secretion by 
tunicamycin in both WT and VLDLR-deficient mice (77).  Taken together, these 
results suggest that VLDLR contributes to the development of hepatic steatosis 
induced by pharmacological ER stress and high fat diet.  The results are 
suggestive of an increased role of lipid delivery, rather than reduced secretion, 
metabolism or increased lipogenesis (77).   
 
These laboratory studies support the hypothesis that ER stress has a role in the 
pathogenesis and progression of NAFLD, by providing evidence of associations 
between ER stress, metabolic alterations and TG accumulation.  The results also 
demonstrate how dietary factors relating to SFA and PUFA could potentially be 
responsible for some of the heterogeneity in the NAFLD patient population. 
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1.6 AIMS OF RESEARCH 
Several complex and interacting signaling networks may be relevant in the 
development of NAFLD; discerning the ways in which each of these 
mechanisms may cause dysfunction and contribute to pathogenesis may be key 
to prevention, treatment and reducing the significant burden of this increasingly 
common disease.  This project primarily focuses on oxidative stress and ER 
stress –these may have a role in the pathogenesis of NASH and cross talk 
between components of these complex signaling pathways is likely. Although it 
is known that Nrf2 has a key role in cellular defence against oxidative stress, the 
role of Nrf2 in different environments of cellular stress has not been fully 
explored.  Liver and adipose tissues from a dietary mouse model of NASH have 
been used to assess the role of Nrf2 in inflammation, ER stress and metabolic 
disturbance.  A cell culture model has been used to further elucidate mechanisms 
of cellular crosstalk between ER and oxidative stress pathways.  
 
Therefore, this project has two aims: 
1. To further explore the role of Nrf2 in NAFLD by examining the effect of 
pharmacologically upregulated Nrf2 on metabolic, inflammatory and ER stress 
markers in a dietary induced mouse model of NASH. 
2. To investigate the role of Nrf2 in response to ER stress in vitro. 
 
48 
Chapter 2 Methods and materials 
2.1 Materials and Reagents 
Materials used were from SigmaAldritch unless stated otherwise. The recipes of 
buffers and solutions commonly used in this project are described in Table 2.1.   
 
Table 2-1. Details of buffers and solutions used in this project 
Buffer Constituent materials 
RIPA buffer 50mM Tris, 150mM NaCl, 0.1%SDS, 0.5% sodium 
deoxycholate, 1% Triton X 100 
Modified RIPA buffer 10ml RIPA, 50ul 200mM sodium orthovanadate, 
10ul 1M dithiothreitol, 1 tablet complete mini 
EDTA-free cocktail protease inhibitor (Roche 
Diagnostics), 100ul Halt TM single use cocktail 
phosphatase inhibitor  (ThermoScientific).   
10X Transfer buffer 
(TB) 
Tris 300g, Glycine 1440g, fill to 10L with dH2O 
SDS Running buffer 10% (v/v) 10% TB, 1% (w/v) SDS in dH20 
MOPS running buffer 1% (v/v) 3-(N-morpholino)propanesulfonic acid in 
dH20 
Transfer buffer 20% (v/v) methanol, 10% 10X TB, 0.1% SDS in 
dH20 
RLT buffer 10ml RNEasy Mini Kit RLT (Qiagen), 10ul 
mercaptoethanol  
Enhanced 
chemiluminescence 
(ECL) solution 1 
500ul 250mM luminol in DMSO, 220ul 90mM 
coumaric acid in DMSO, 5mL 1M Tris HCl pH8.5 
made up to 45ml with dH20 
(Stored in the dark at 5C) 
Sodium dodecyl sulfate 
(SDS) polyacrylamide 
gels  
 
Polyacrylamide Ultra Pure ProtoGel (National 
Diagnostics), 1.5M Tris-HCl pH8 or 1.0M Tris-HCl 
pH6.5, 10% (w/v) SDS, N,N,N’,N’-Tetramethyl-
ethylenediamine (Sigma), 1% ammonium persulphate 
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(Proportions according 
to standard protocols) 
in dH2O 
Tris buffered saline 
tween (TBST) 
20X TBS: Tris-HCl 48.4g, NaCl 192g, pH7.6 
TBST: 1X TBS, 0.1% (v/v) tween-20. 
BSA blocking buffer 5% w/v BSA in TBST 
ECL solution 2 
 
32uL 30% hydrogen peroxide, 5ml 1M Tris HCl 
pH8.5 made up to 45ml with dH2O. 
(Stored in the dark at 5C) 
 
2.2 Animal experiments 
Prior to starting in the lab, wild type C57Bl6 mice were separated into two age- 
and weight-matched groups and placed onto either 1) normal chow (NC) or 2) a 
high fat diet with high fructose in drinking water (HFFr), for 24 weeks.  The 
HFFr mice were fed a diet comprised of 60% fat and were given drinking water 
containing 30% fructose.  Within in each group, mice were treated for a further 
six weeks with either the compound TBE-31, a pharmacological Nrf2 up-
regulator, or with dimethyl sulfoxide (DMSO) for control.   TBE-31 was given to 
mice via oral garage 3 times a week at a concentration of 5nmol/g body weight. 
 
There were 4 groups based on diet (NC or HFFr) and treatment with (+) or 
without (-) TBE-31.  At 30 weeks, the mice were culled using a schedule 1 
protocol, and tissues were collected.  Animals were treated and housed humanely 
and in accordance with the UK Animals (Scientific Procedures) Act, 1986.  Liver 
and adipose tissue samples were kindly received from Dr Ritu Sharma (Hayes 
Lab).  Other results from the Hayes Lab indicated that the effect of the HHFr diet 
on wild type mice closely resembled the human NASH phenotype, with hepatic 
steatosis, inflammation and insulin resistance.   
2.3 Cell culture 
Immortalised mouse epithelial fibroblasts (MEF) cells were maintained in 
Iscove’s Modified Dulbecco’s Medium (IMDM), supplemented with 10% fetal 
calf serum (FCS), 1% 100X Insulin-transferrin-selenium (ITS) (final 
concentrations of 0.01mg/ml insulin, 5.5ug/ml transferrin and 6.7ng/ml sodium 
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selenite) and 1.5nM recombinant human epidermal growth factor (EGF) (all 
from ThermoFisher Scientific).  Culture flasks and wells were coated with 0.1% 
gelatine in phosphate buffered solution (PBS) for at least 30mins at room 
temperature; this was removed prior to seeding.  Immortalised wild type (WT), 
Nrf2-/-  cells and Keap1-/-  cells were kindly received from the Dinkova-Kostova 
Lab.  These were cultured and maintained at 37°C with 5%CO2. 
2.3.1 Treatment conditions: ER stress induction 
2.3.1.1 Initial glucose starvation and tunicamycin studies with WT and Nrf2-/-  
MEFs 
MEF cells were seeded into 6 well plates the following seeding densities and 
labelled accordingly: WT 3x105/well and Nrf2-/- 5x105/well.  Cells were left 
overnight, before being treated with 0.5ml/mg of sulforaphane (kindly received 
from the Dinkova-Kostova lab) or dimethyl sulfoxide (DMSO) for control, in 
fresh supplemented IMDM media (as above).  After 3 hours of treatment, media 
was removed, cells were washed twice with phosphate buffered saline (PBS) and 
time 0 (T=0) was recorded. 
2.3.1.2 Experiment 1. Glucose deprivation time-course 
At T=0, cells were incubated in glucose free Dulbecco’s Modified Eagle 
Medium (DMEM) (ThermoFisher Scientific), without FCS, supplemented with 
either 0.5ml/mg sulforaphane or DMSO.  Cells were collected in RIPA buffer at 
specific time points; T=0, 1, 2, 4, 6, 8 hours. At each time point, 2 wells of cells 
were collected (with the exception of the Nrf2-/- 8 hour time point). 
2.3.1.3 Experiment 2. Tunicamycin treatment 
At T=0, cells were incubated in supplemented IMDM as described above, with 
the addition of either 1) Tunicamycin (Sigma) at concentration of 5ug/ml or 
DMSO for control.  Sulforaphane or DMSO control treatments were also added 
to the fresh media and continued throughout the experiment.  After 6 hours, 2 
wells of cells were collected for each treatment group.  
 
After preliminary experiments, it was decided to utilise a longer pre-treatment of 
16-24hours with sulforaphane 0.5ul/ml or DMSO vehicle control and to 
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discontinue this during ER stress induction.   This was to eliminate any potential 
interactions between Tunicamycin and Sulforophane during ER stress induction 
and provide more useful information.  The cells seeding densities were also 
amended to reflect the longer treatment to: WT 2x105/well and Nrf2-/- 
3.5x105/well. 
2.3.1.4 Experiment 3. Glucose starvation time-course 
Cell seeding was followed as above, with the addition of Keap1-/- MEF cells at 
density of 1.5x105/well.  Cells were left overnight before being treated with 
0.5ul/ml of sulforaphane or DMSO control in fresh media.  After 16 hours of 
treatment, cells were washed twice with PBS before incubation in glucose free 
DMEM only.  Cells were collected at the specified time-points, with 2 wells 
pooled for each time point for protein analysis. 
2.3.1.5 Experiment 4. Tunicamycin treatment  
Cell seeding and sulforaphane pre-treatment was followed as previously 
described.  After 16 hours of treatment, cells were washed twice with PBS and 
then incubated in supplemented IMDM media with Tunicamycin 5ug/ml or 
DMSO. After 6 hours, 3 wells were pooled for each treatment for protein 
analysis.  This experiment was performed in duplicate.   
2.3.1.6 Experiment 5. Treatments for mRNA collection 
WT and Nrf2-/-  MEF cells were seeded into 6 well plates as above. After settling 
overnight cells were washed twice with PBS.  Cells were then treated with either: 
1) supplemented IMDM media; or 2) glucose free DMEM supplemented with 
10% FCS only; or 3) supplemented IMDM media with 5ug/ml Tunicamycin.  
Cell lysates were collected at specified time-points using 100ul of RT buffer 
(Qiagen) plus EDTA (0, 6, 12 and 24 hours), and 2 wells of cells were pooled for 
mRNA analysis. 
2.4 Protein lysate preparation and immunoblotting 
2.4.1.1 Adipose tissue preparation 
 Protein lysates were prepared from adipose tissue samples from 3 mice in each 
group: Tissue was homogenised in 600uL of modified RIPA buffer (as described 
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above, plus 20ul 0.1M phenylmethylsulfonyl fluoride).  Samples were then 
centrifuged at 4°C for 15mins and the cytoplasmic extract was isolated.  
2.4.1.2 MEF cell lysates  
Cells were collected using modified radioimmunoprecipitation assay (RIPA) 
buffer, as described in Recipes.  Samples were placed on ice before undergoing 
protein estimation or were frozen in liquid nitrogen and stored at -20°C.   
2.4.3 Quantitative protein estimation 
Protein estimation was performed using the detergent-compatible (DC) assay; 
absorbances were performed in duplicate and used to calculate sample protein 
content by comparison to bovine serum albumin (BSA) standards of known 
concentration.  Protein levels of lysates were normalised and prepared for 
immunoassay with the addition of 4X lithium dodecyl sulphate sample loading 
buffer, 20X sample reducing agent (both NuPAGE, Invitrogen) and dH20.  
2.4.4 Western blotting 
Electrophoresis was used to separate proteins in the protein lysate in sodium 
dodecyl sulfate (SDS)-polyacrylamide gels, or pre-cast Bis-Tris 4-12% Midi gels 
(Novex).  SDS-PAGE casting followed standard Laemmli protocols; buffers 
used are described in recipes section and gel percentages and electrophoresis 
conditions were optimised for sample numbers and the proteins of interest.  
Standard running conditions were 200V for 55mins, and gels were transferred to 
polyvinylidene difluoride membranes at 60V for 75mins.  Membranes were 
blocked in 5% BSA or 5% powdered milk in tris-buffered saline with tween 
(TBST) for at least 1 hour before placement into primary antibody.  Membranes 
underwent thorough washing in TBST between placement in primary and 
secondary antibodies, and prior to enhanced chemiluminescence (ECL) 
development.  Blots were developed by exposure to film in a darkroom following 
ECL application, for certain primary antibodies blots were developed with 
sensitive Immobilon Chemiluminescent HRP substrate (Millipore). Results were 
assessed with densitometry using Image J software and normalised relative to 
sample β-actin levels. 
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2.4.5 Antibodies 
Primary antibodies detailed in Table 2.2 below were used to detect a panel of 
proteins involved in ER stress, inflammation and fatty acid metabolism.  
Monoclonal antibody against β-actin was used to assess protein-loading levels. 
Table 2-2. Details of primary antibodies used in this project 
 
Primary antibody Size 
(kDa) 
Company Species  Type 
Nqo1 31 In-house Rabbit Monoclonal 
Actin-beta (HRP) 39 Sigma Mouse Monoclonal 
Xbp1 29 
40 
Abcam Rabbit Polyclonal 
Il6 23 Abcam Rabbit Polyclonal 
Jnk 46 
54 
Cell Signaling 
Technology 
Rabbit Polyclonal 
phospho-SAPK/Jnk 
(Thr183/Tyr185) 
46 
54 
Cell Signaling 
Technology 
Rabbit Polyclonal 
Tnfα 17 
25 
Cell Signaling 
Technology 
Rabbit Polyclonal 
Acaa1 44 ThermoScientific Rabbit Polyclonal 
Scd-1 37 Cell Signaling 
Technology 
Rabbit Polyclonal 
Acox1 74 Abcam Rabbit Polyclonal 
Fabp 10-15 Abcam Rabbit Polyclonal 
Ces1 ~60 ThermoScientific Rabbit Polyclonal 
Pparα 52 Abcam Rabbit Polyclonal 
Chop 27 Cell Signaling 
Technology 
Rabbit Monoclonal 
Eif2α 38 Cell Signaling 
Technology  
Rabbit Polyclonal 
phospho-Eif2α (ser51) 38 Cell Signaling 
Technology 
Rabbit Polyclonal 
Pdi 57 Cell Signaling 
Technology 
Rabbit Monoclonal 
Ero1-Lα 60 Cell Signaling 
Technology 
Rabbit Polyclonal 
Bip 78 Cell Signaling 
Technology 
Rabbit Polyclonal 
Perk 140 Cell Signaling 
Technology 
Rabbit  Monoclonal 
phospho-Perk (Thr980) 170 Cell Signaling 
Technology 
Rabbit Monoclonal 
Ire1α 130 Cell Signaling 
Technology 
Rabbit Monoclonal 
Xbp1-spliced 54 BioLegend 
 
Rabbit Polyclonal 
54 
Atf4  49 Cell Signaling 
Technology 
Rabbit Monoclonal 
Atf6α  50 (f) 
90 
Santa Cruz 
Biotechnology 
Rabbit Polyclonal 
phospho-Ire1α (Ser724) 110 ThermoScientific Rabbit Polyclonal 
P58IPK 58 Cell Signaling 
Technology 
Rabbit Monoclonal 
Nrf2 97-100 Cell Signaling 
Technology 
Rabbit Monoclonal 
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2.5 Quantitative reverse transcription polymerase chain reaction (qRT-
PCR)  
The RNeasy Mini Kit (Qiagen 74104, 74107) was used to prepare cDNA from 
sample mRNA following manufacturer’s protocols.  A nanodrop 
spectrophotometer was used to estimate RNA in samples. cDNA was prepared 
from mRNA using the Omniscript RT 200 kit (Qiagen) as per instruction, it was 
assumed that 1ug RNA would produce 1ug cDNA.  For animal tissue 
experiments, mRNA previously extracted from mouse liver tissue was used to 
prepare cDNA.  The number of samples from each treatment group was as 
follows: NC(-) 7, NC(+) 8, HFFr(-) 7, HFFr(+)7. 
 
Standard qRT-PCR was performed using 12.5uL of probe mix (comprised of 
4.5ul Taqman Universal Master Mix II, no UNG (Applied Biosystems), 0.75ul of 
specific probe and made up to 12.5uL with dH20), with 2.5ug of sample cDNA. 
(Amounts of dH2O and cDNA were adjusted for some probes.) Probes used are 
listed in Table 2.3.  SYBR Green PCR Master Mix (Applied Biosystems) was 
used for reverse and forward Xbp1-s primers.  Triplicates were performed for 
each sample, and actin and/or S18 were used as housekeeping genes. Plates were 
sealed and centrifuged at 1980g for 3mins.  Samples were then run using 7500 
Real-Time PCR System (Applied Biosystems) on a standard 90min qRT-PCR 
cycle.  
 
Table 2-3. Details of probe primers used for rt-qPCR 
Probe 
primer 
Assay ID  
(Applied Biosystems) 
Label 
18S 4319413E VIC 
F4/80  Mm00802529_m1 Fam 
B220  Mm01293577_m1 Fam 
Nos2 Mm00440502_m1 Fam 
Gsr Mm00439154_m1 Fam 
Pparγc1 Mm01208835_m1 Fam 
G6pc Mm00839363_m1 Fam 
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Cd68 Mm03047340_m1 Fam 
Elovl6 Mm00851223_s1 Fam 
Itgam Mm00434455_m1 Fam 
Cd36 Mm00432403_m1 Fam 
Pparγ Mm00440940_m1 Fam 
Ccl2 Mm00441242_m1 Fam 
Mpo Mm01298424_m1 Fam 
Rela Mm00501346_m1 Fam 
Perk Mm00438700_m1 Fam 
Ire1α Mm00470233_m1 Fam 
Atf4 Mm00515325_g1 Fam 
Chop Mm01135937_g1 Fam 
Bip Mm00517691_m1 Fam 
P58IPK Mm01225042_m1 Fam 
Erdj4 Mm01622956_s1 Fam 
Dnajb11 Mm00518196_m1 Fam 
Edem1 Mm00551797_m1 Fam 
Serp1 Mm00472715_m1 Fam 
Ero1α Mm00469296_m1 Fam 
Atf6 Mm01295319_m1 Fam 
Atf3 Mm00476032_m1 Fam 
Eif2α Mm01289723_m1 Fam 
Xbp1(total) Mm00457360_m1 Fam 
β Actin Mm00607939_s1 VIC 
Xbp-1 
spliced 
Xbp1 5’ and 3’ (SYBR) spliced – 
CTGAGTCCGAATCAGGTGCAG 
GTCCATGGGAAGATGTTCTGG 
SYBR 
Green 
 
2.6 Statistical analysis 
All results are given in terms of relative fold change compared to WT control.  
Two-way ANOVA with Bonferroni post-test analysis was performed for rtPCR 
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data.  Graphs and images were produced using ImageJ and Prism GraphPad 
software.  
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Chapter 3 Investigating the pathogenesis of NASH in mice fed a High Fat 
plus High Fructose diet 
3.1 Introduction 
The aim of this chapter is to investigate the role of Nrf2 using a diet induced 
mouse model of NASH.  Experiments were performed to investigate the role of 
Nrf2 in NASH by assessing the effects of pharmacological up-regulation of Nrf2 
by the compound TBE-31 in wild type mice with diet-induced NASH.  TBE-31 
is a potent Nrf2 activator through interaction with Keap1 (79).  Mice were 
divided into 4 groups based on diet (NC or HFFr) and TBE-31 treatment: 
 
1. NC (-) Normal chow diet with DMSO  
2. NC (+) Normal chow diet with TBE-31 
3. HFFr (-) High fat, high fructose diet with DMSO 
4. HFFr (+) High fat, high fructose diet with TBE-31 
 
RtPCR was performed on liver samples (NC(-) n=7, NC(+) n=8, HFFr(-) n=7, 
HFFr(+) n=7), to analyse hepatic mRNA expression of a selection of genes 
involved with inflammation, oxidative stress and metabolism.  Western blotting 
was performed on adipose tissue (n=3 mice per intervention group) to assess 
protein expression of ER stress markers, inflammatory proteins and metabolic 
pathways.  
 
3.2 Results 
3.2.1 Comparison of mRNA expression in the liver 
The graphs presented in Figure 3.1 depict results for genes with reasonable 
interpretable data2.  These results demonstrate that the mRNA levels of nitric 
oxide synthase (Nos2), macrophage marker F4/80 and B-lymphocyte marker 
B220, are all upregulated in the livers of HFFr (-) mice, compared to control 
mice, suggestive of an inflammatory process within the livers induced by the 
HFFr diet.  These increases were not found in the livers of HFFr (+) mice, 
                                                
2 Other genes assessed included: G6pc, Txn1, Gstm1, Mcr1, Atf3, G6pc, Cd68, 
Itgam, Cd36, Pparγ, Ccl2, Mpo and Rela. 
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implying that the addition of TBE-31 compound acted to attenuate an 
inflammatory process.  As the TBE-31 compound activates Nrf2, it is possible 
that increased Nrf2 activity ameliorated the inflammatory changes induced by 
the HFFr diet.  There is also a trend towards down-regulation in mRNA levels of 
Gsr, involved in glutathione recycling and Pparγc1, involved in defence against 
oxidative stress, in both HFFr (+) and HFFr (-) mice compared to NC mice.  This 
could suggest either that mice fed the HFFr diet experience less oxidative stress, 
or that mice fed the HFFr diet have a reduced ability to respond to oxidative 
stress. Although the latter option is more in keeping with the increased markers 
of inflammation observed. 
 
 
Figure 3.1. Relative expression of mRNA in the liver of mice on normal 
chow (NC) or high fat high fructose (HFFr) diets, with the addition of either 
DMSO (control) or the compound TBE-31.  
N= 6-7 mice per group, significance compared to NC (DMSO) except where 
indicated with bars, *P ≤0.05; ** P ≤0.01; *** P ≤0.001 
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3.2.2 Comparative protein abundance in adipose tissue  
Proteins assessed in adipose tissue included the inflammatory markers Jnk, 
phospho-Jnk and Il6.  Many classical ER stress response proteins were analysed 
including components of the Perk arm of the UPR (Perk, phospho-Perk, Eif2α 
and Chop) as well as Xbp1 (Ire1α UPR pathway) and Atf6.  Expression levels of 
ER redox enzymes Pdi and Ero1α were also investigated.  Proteins involved in 
lipid homeostasis analysed included the lipogenic enzyme Scd1, involved in fatty 
acid biosynthesis.  Lipid catabolism was investigated by assessing levels of the 
first and last enzymes in mitochondrial β-oxidation, acyl-CoA oxidase 1 (Acox-
1) and acetyl-CoA acyltransferase (Acaa) respectively.  Expression of Fabp was 
analysed, as was carboxylesterase 1 (Ces1), an enzyme involved in fatty acid 
mobilisation and VLDL secretion; Ces1 hydrolyses TG and is localised to the ER 
(80).   
 
Individual variation between mice meant that none of the results from western 
blotting reached levels of statistical significance.  The data from adipose tissue 
was found to be too variable to interpret and is therefore not shown.   
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3.3 Discussion 
Experiments were performed to investigate the role of Nrf2 in NASH by 
assessing the effects of pharmacological up-regulation of Nrf2 in wild type mice 
by the compound TBE-31, with NASH induced by HFFr diet that closely 
resembled the human disease. 
 
The results are suggestive of an inflammatory process occurring in the livers of 
mice on an HFFr diet, but this was not demonstrated in adipose tissue.  It is 
possible that this may be related to the time course of the experiment: Stanton et 
al used a high fat and cholesterol diet to study NASH in mice, and demonstrated 
that inflammatory markers were up-regulated in adipose tissue and liver 
differentially, with adipose tissue typically showing inflammation earlier at 6-16 
weeks, and the liver at later stages (26 weeks) (81).  As the mice in the current 
study were culled after 30 weeks of NC or HFFr diet, this would reflect a later 
stage of disease.  The lack of significant adipose tissue inflammation may also be 
due to the sample size of n=3 used in the current project.  
 
ER stress and the adaptive pathways resulting in the UPR are known to affect 
lipid metabolism and steatosis (77).  In experiments using an ER stress-inducing 
drug in mice, Jo et al (77) found that expression of ER response genes is not 
significantly altered in tissues other than liver, however this was using an ER 
stress inducer injected intra-peritoneally, which may have influenced more local 
effects on the liver.  The lack of significant results of ER stress proteins in 
adipose tissue in this project may support this observation, as no clear evidence 
of UPR induction was demonstrated.  However, analysis of a larger sample may 
reveal trends.  The enzymes involved in metabolism and inflammation also did 
not show a clear pattern of expression in adipose tissue.  However, this again 
may be related to the sample size used or the age of the mice in this study, and 
requires further investigation. These results demonstrate both the complexity of 
the interacting pathways involved in NASH, confounded by variation between 
individual mice.  
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Chapter 4 Unravelling the role of Nrf2 during endoplasmic reticulum stress 
in vitro 
4.1 Introduction 
The purpose of this study was to determine whether Nrf2 activity interacts with 
components of the UPR under conditions of ER stress, and to characterize the 
influence of Nrf2 during the cellular response to ER stress.  ER stress markers 
and classical components of the UPR under conditions of ER stress were 
examined in cells that lacked Nrf2, or had pharmacologically or genetically 
upregulated Nrf2 activity. 
 
This study utilized an in vitro model of mouse epithelial fibroblasts (MEFs), 
comparing control cells (WT) with cells lacking Nrf2 (Nrf2-knockout, Nrf2-/-) 
and cells with increased Nrf2 activity due to loss of Keap1 suppression (Keap1-
knockout, Keap1-/-).  The effect of pharmacologic Nrf2 up-regulation in ER stress 
was also assessed using WT cells pre-treated with the Nrf2 inducer (SFN). SFN 
is an isothiocyanate that activates Nrf2 through Keap1 (82).  ER stress was 
induced using methods of glucose starvation and tunicamycin treatment (Tm):  
Glucose starvation produces ER stress via blocking N-linked glycosylation and 
reducing cellular ATP, tunicamycin treatment causes inhibition of first enzyme 
of glycoprotein synthesis, resulting in accumulation of glycoproteins within the 
ER (83).  To detect ER stress and characterize the UPR, the mRNA and protein 
expression of a panel of well-established components of the unfolded protein 
response was analyzed using western blotting and quantitative real-time 
polymerase chain reactions (q-rtPCR).  
 
4.2 Results 
4.2.1 Confirming established Nrf2 cell status 
Western blot and rtPCR data of the classical Nrf2 target, Nqo1 was assessed to 
confirm cells were expressing the expected Nrf2 phenotype.  Results demonstrate 
that basal levels of Nqo1 were dependent on Nrf2 status, with both protein and 
mRNA extremely reduced in Nrf2-/- cells and strongly upregulated in Keap1-/- 
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cells compared to WT.  Nqo1 protein expression was also found to be up-
regulated in SFN treated cells, indicating that the pretreatment was able to 
adequately activate Nrf2. Western blotting of Nrf2 also demonstrated increased 
levels in both Keap1-/- and SFN treated cells, and no expression in Nrf2-/-, further 
confirming Nrf2 status in cells.  Tunicamycin treatment had no evident effects on 
Nqo1 protein expression.  These results can be observed in Figures 4.2-4.5 and 
4.8. 
4.2.2 The response of wild type MEF cells to ER stress 
Western blotting results shown in Figures 4.1-4.4 demonstrated that components 
of the UPR were not highly expressed in WT cells at baseline.  When WT cells 
were subject to ER stress, either by glucose starvation or tunicamycin treatment, 
there was prominent induction of Atf4, Bip and Chop, as well as increases in 
levels of Eif2α, Pdi, Perk and Ire1α.  
 
 
Figure 4.1 Western blot results of Experiment 1: Glucose starvation time 
course. ER stress response markers in MEF cells incubated in glucose-free 
DMEM for up to 6 hours. Key: WT= wild type; SFN = Sulforaphane 
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4.2.3 Components of the UPR are consistently upregulated in cells lacking 
Nrf2 under basal conditions  
In Experiment 1 it was observed that cells lacking Nrf2 had upregulated protein 
expression of ER stress markers at baseline: Levels of Perk, Eif2α, phospho-
Eif2α, Chop, Ero1α, Pdi and Ire1α were all increased at T=0 in Nrf2-/- cells, 
compared to WT.  In keeping with these results, baseline protein levels of Pdi, 
Ire1α, Eif2α and phsopho-Eif2α were demonstrably increased in Nrf2-/- cells in 
Experiment 2. Chop was also increased basally, although this is not seen in 
Figure 4.2 due to differences in exposure. In addition, levels of both unspliced 
and spliced Xbp1 protein were basally increased in Nrf2-/- cells, providing further 
evidence that UPR components are basally upregulated in cells lacking Nrf2.  
The results of further glucose deprivation (Experiment 3, shown in Figure 4.3) 
and tunicamycin treatment (Experiment 4, shown in Figure 4.4) confirmed the 
finding that components of the UPR were raised at baseline in cells lacking Nrf2.  
Specifically, basal levels of Eif2α, phospho-Eif2α, Ero1α, Pdi, Ire1α and Xbp1-s 
were found to be consistently increased in Nrf2-/- cells.  However, levels of Perk 
and phospho-Perk did not appear to be basally increased in Nrf2-/- cells in further 
experiments. 
 
There are a number of possible reasons that could account for these findings.  
Components of the UPR may be constitutively activated in Nrf2-/- cells, or cells 
lacking Nrf2 may have heightened sensitivity to ER perturbations.  Increased 
basal levels of Ero1α and Pdi could be caused by homeostatic readjustment to 
alterations in the ER REDOX homeostasis caused by reduced cellular 
antioxidant capacity (such as reduced glutathione), in the absence of Nrf2.  
 
The upregulated protein levels of Perk, Eif2α, phospho-Eif2α and Chop suggests 
that lack of Nrf2 increases expression and/or activation of components of the 
Perk arm of the UPR.  However, the general upregulation of other UPR 
components including Ire1α in Nrf2-/- cells suggest general induction of the UPR 
as well as Perk arm activation.  It should also be noted that if Nrf2-/- cells are 
under constitutive ER stress, the Perk arm may be preferentially activated to 
stimulate pro-apoptotic pathways (65). 
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Figure 4.2. Western blot results of Experiment 2: ER stress response 
markers in MEF cells treated with Tunicamycin. Cells were treated with 
Tunicamycin or control (DMSO) for 6 hours. Key: N =Nrf2-/-; W= wild type; 
S = WT + Sulforaphane.  
 
4.2.4 The basal expression of ER stress markers in sulforophane treated WT 
cells 
Experiment 1 demonstrated that WT cells treated with SFN had basally reduced 
protein expression of Eif2α, phospho-Eif2α and Ero1α compared to WT cells.  
Reduction of these ER stress markers in SFN treated cells indicates that 
pharmacologically upregulated Nrf2 reduces the basal expression requirement 
for ER homeostasis. Perk expression appeared to be similar to WT levels in SFN 
treated cells, which is surprising with the observed reduction in downstream 
effectors of the Perk UPR arm. In Experiment 2, basal protein expression of ER 
stress markers did not dramatically differ between SFN treated and WT cells, 
with the exception of Eif2α.   In contrast to findings in Experiment 1, Eif2α 
protein level was initially increased in SFN treated cells compared to WT. These 
results are ambiguous, but raise the possibility that either increased Nrf2 activity 
(mediated by SFN) or SFN itself is moderating the Perk signalling cascade.   
 
From initial results, it was postulated that the lack of Nrf2 might increase 
susceptibility to ER stress, and conversely that up-regulation of Nrf2 might 
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augment resistance to ER stress.  Keap1-/- cells were introduced in Experiments 3 
and 4 to test this hypothesis.  A clear pattern with any specific arm of the UPR 
was not able to be confirmed, so a larger panel of ER stress markers and UPR 
components was assessed in further experiments.  
 
 
Figure 4.3 Western blot results of Experiment 3: Glucose starvation time 
course. ER stress response markers in MEF cells incubated in glucose-free 
DMEM for up to 6 hours. Key: WT= wild type; SFN = Sulforaphane.  
 
4.2.5. Components of the UPR are differentially expressed in Keap1-/- cells 
under basal conditions 
Western blotting results indicate that under basal conditions, Keap1-/- cells 
express increased protein levels of Perk and phospho-Perk, slightly increased 
Atf6 (90kDa) and reduced levels of Pdi and p58IPK.  However, despite increased 
basal phospho-Perk, protein levels of downstream effectors phospho-Eif2α, Atf4 
and Chop were not increased at baseline in Keap1-/- cells.  Taking into 
consideration the findings that Nrf2-/- cells had increased downstream effectors of 
the Perk arm of the UPR, these results provide further indication that Nrf2 
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modulates the activity of Perk, possibly with uninhibited Nrf2 repressing 
phospho-Perk kinase activity in a negative feedback cycle. 
4.2.6 The response of Nrf2-/- MEFs, Keap1-/- MEFs and SFN treated WT cells 
to ER stress induction 
4.2.6.1 WT cells 
When subject to glucose starvation, components of the UPR were induced in a 
time-dependent manner and peaked at 4-6 hours regardless of cell type, 
demonstrated by expression levels of Atf4, Chop and Bip shown in Figure 4.3.  
In WT cells, expression of these components as well as phospho-Eif2α, phospho-
Ire1α and spliced and unspliced forms of Xbp1, appear to peak at 4hours.  (The 
lack of observable Chop expression in WT cells in Experiment 1 was suspected 
to be a false negative finding due to difficulties obtaining western blots for Chop 
in this experiment.  This was confirmed following evident Chop induction in WT 
cells in further experiments.)  Tm treatment also strongly induced the expression 
of Atf4, Chop and Bip in WT cells as well as other cell types.   
4.2.6.2 Nrf2-/-cells 
Expression of the downstream Perk signalling molecules Atf4 and Chop was 
induced in Nrf2-/- cells subject to ER stress induction.  When cells were deprived 
of glucose this occurred notably at T=4hrs, but to a lesser extent than in WT 
counterparts at this time-point. Taken that these were seen to be increased at 
base-line; this finding could be explained by cells with constitutively increased 
Perk activity being less able to respond to ER stress.  Bip was induced in Nrf2-/- 
cells, to a lesser extent than WT, by both glucose starvation and Tm challenge.  
In response to Tm challenge, Xbp1 protein expression in Nrf2-/- cells did not 
increase from basal levels but remained higher in Nrf2-/- than in WT cells 
following Tm.  This could be explained if Xbp1 was already being maximally 
expressed. These results suggest that Nrf2-/- cells are less able to mount an 
effective, adaptive UPR response. 
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Figure 4.4 Western blot results of Experiment 4, performed in duplicate: 
ER stress response markers in MEF cells treated with Tunicamycin. Cells 
were treated with Tunicamycin or control (DMSO) for 6 hours. Key: N 
=Nrf2-/-; W= wild type; S = WT + Sulforaphane; K=Keap1-/-. 
 
4.2.6.3 WT + SFN cells 
Cells treated with SFN showed an increased expression of Eif2α throughout the 
glucose deprivation time-course compared to WT cells alone.  The induction of 
UPR components in cells treated with SFN also appears to occur at a later time-
point, at around 6 hours. This again provides evidence suggesting that increased 
Nrf2 activity in cells with SFN treatment modulates the activity of the Perk arm 
of the UPR.  The response to Tm challenge in SFN treated cells was very similar 
and in keeping with the response of WT cells.   
4.2.6.4 Keap1-/- cells 
The general pattern of increased expression of UPR components such as Bip, 
phospho-Eif2α, Atf4 and Chop was also seen in Keap1-/- cells subject to ER 
stress. The induction of ER stress markers by glucose starvation was observed to 
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occur more strongly at the later time-point of 6hours in Keap1-/- cells, compared 
to 4hours in WT cells.  Keap1-/- cells appear to have a more gradual response to 
glucose starvation, possibly peaking later than the time-course studied.  This 
supports the hypothesis that cells with up-regulated Nrf2 might be less 
susceptible to ER stress.  In response to Tm challenge, Xbp1, the 50kDa 
fragment of Atf6 were strongly induced in Keap1-/- cells compared to WT cells, 
demonstrating that the response to ER stress is altered in cells with increased 
Nrf2 activity, and also engages the Ire1a and Atf6 arms of the UPR.  
4.2.7 Basal mRNA expression of ER stress markers in Nrf2-/- and Keap1-/- 
cells compared to WT 
Results of q-rtPCR are demonstrated in Figures 4.5 to 4.7 (glucose deprivation) 
and Figures 4.8 to 4.10 (tunicamycin challenge).  These results represent a set of 
triplicates for each sample from one experiment; therefore, error bars indicate 
experimental error and only limited conclusions may be inferred from these 
results. 
4.2.7.1 Nrf2-/- cells 
Consistently with protein expression, q-rtPCR of glucose deprivation showed 
significantly increased basal mRNA levels of total-Xbp1, Atf4 (both 
approximately 3 fold), Chop (10 fold), and Ero1α (10-15 fold) in Nrf2-/- cells 
compared to WT.  However, increases in these genes did not reach significance 
in data from tunicamycin challenge, but instead demonstrated a trend towards 
increase.    
4.2.7.2 Keap1-/- cells 
Compared to WT, Keap1-/- cells demonstrated a trend of basal increase in mRNA 
levels of Ire1α, Eif2α, Chop, total-Xbp1 and spliced-Xbp1 (the latter two 
reaching significance in glucose starvation and Tm, respectively).  These 
findings appear to contradict the protein expression data, however fold changes 
were not dramatically increased and it is also possible that mRNA is undergoing 
increased post-transcriptional or post-translational degradation.  The lack of 
increased Perk mRNA expression may indicate that phospho-Perk protein 
accumulation in Keap1-/- cells is not related to upregulated expression.  
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Figure 4.5 Glucose starvation time course rtPCR results: Relative mRNA 
expression of ER stress markers in MEF cells incubated in glucose-free 
DMEM for up to 24 hours. ER stress response markers in. Key: WT wild 
type; SFN = Sulforaphane.  Data presented is from one experiment. 
Significance compared to corresponding WT time-point: *P ≤0.05; ** P 
≤0.01; *** P ≤0.001. 
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Figure 4.6 Glucose starvation time course rtPCR results: Relative mRNA 
expression of ER stress markers in MEF cells incubated in glucose-free 
DMEM for up to 24 hours. ER stress response markers in. Key: WT= wild 
type; SFN = Sulforaphane.  Data presented is from one experiment. 
Significance compared to corresponding WT time-point: *P ≤0.05; ** P 
≤0.01; *** P ≤0.001. 
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Figure 4.7 Glucose starvation time course rtPCR results: Relative mRNA 
expression of ER stress markers in MEF cells incubated in glucose-free 
DMEM for up to 24 hours. ER stress response markers in. Key: WT= wild 
type; SFN = Sulforaphane.  Data presented is from one experiment. 
Significance compared to corresponding WT time-point: *P ≤0.05; ** P 
≤0.01; *** P ≤0.001. 
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4.2.8 Gene expression in response to ER stress  
Cells were stressed using methods of either glucose starvation or Tm treatment, 
and mRNA was collected over a 24hour time-course.   
4.2.8.1 WT cells  
When WT cells were subject to glucose deprivation, mRNA expression was 
induced for all of the ER stress markers investigated.  These all followed a 
pattern of levels remaining at baseline or slightly increasing until 24hours, where 
a much larger, maximal induction occurred.  The most notable increase in WT 
cells was in Chop mRNA, which was increased by over 50-fold at 24hours.   
When WT cells were stressed with Tm the pattern of induction followed a more 
time-dependent course, but again with maximal induction occurring at 24hours.      
4.2.8.2 Nrf2-/- cells 
In response to glucose starvation, almost all components of the UPR were 
significantly and dramatically induced in Nrf2-/- cells at 6hours, after which time 
these tapered down and many where reduced compared to WT at 24hours.  This 
contrasts with the induction of many UPR components in WT and Keap1-/- cells, 
which typically peaked at 24hours. The 6-hour peak of UPR targets did not occur 
in Nrf2-/- cells when stress was induced by Tm.  In this situation, the Nrf2-/- cells, 
similarly to WT and Keap1-/- cells, exhibited a time-dependent pattern of 
increasing in UPR induction with maximal response at 24hours.  This could 
potentially mean that Nrf2-/- cells are more sensitive to glucose deprivation than 
other forms of ER stress, and this seems plausible, as Nrf2 regulates numerous 
targets, including genes involved in glucose homeostasis.  
 
Interestingly, Nrf2-/- cells had increased levels of Perk mRNA compared to WT 
cells induced by ER stress regardless of method.  This again strongly suggests 
that Nrf2 has some influence over the expression of Perk and the Perk UPR 
pathway. 
4.2.8.3 Keap1-/- cells 
Induction of mRNA expression in Keap1-/- cells followed very similar patterns to 
WT cells in both glucose deprivation and Tm time-courses.  However, induction 
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of the UPR was to much greater extent in Keap1-/- cells at 24hours compared to 
WT cells.   
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Figure 4.8 Tunicamycin treatment rtPCR results: mRNA expression ER 
stress response markers in MEF cells treated with Tunicamycin for up to 
24hours. Cells were treated with Tunicamycin or control (DMSO) for 6 
hours. Key: WT= wild type; SFN = Sulforaphane.  Data presented is from 
one experiment. Significance compared to corresponding WT time-point: *P 
≤0.05; ** P ≤0.01; *** P ≤0.001. 
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Figure 4.9 Tunicamycin treatment rtPCR results: mRNA expression ER 
stress response markers in MEF cells treated with Tunicamycin for up to 
24hours. Cells were treated with Tunicamycin or control (DMSO) for 6 
hours. Key: WT= wild type; SFN = Sulforaphane.  Data presented is from 
one experiment. Significance compared to corresponding WT time-point: *P 
≤0.05; ** P ≤0.01; *** P ≤0.001. 
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Figure 4.10 Tunicamycin treatment rtPCR results: mRNA expression ER 
stress response markers in MEF cells treated with Tunicamycin for up to 
24hours. Cells were treated with Tunicamycin or control (DMSO) for 6 
hours. Key: WT= wild type; SFN = Sulforaphane. Data presented is from 
one experiment. Significance compared to corresponding WT time-point: *P 
≤0.05; ** P ≤0.01; *** P ≤0.001. 
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4.3 Discussion 
Results herein demonstrate clear differences between cells under basal conditions, 
with a generalised increase in the expression of ER chaperone and UPR pathway 
proteins in Nrf2-/- cells compared to WT, providing evidence that Nrf2-/- cells 
may be subject to constitutive ER stress.   The oxidoreductins Ero1α and Pdi 
were consistently basally upregulated in Nrf2-/- cells, indicative of homeostatic 
readjustment to alterations in the ER REDOX potential in the absence of Nrf2.   
 
Basal protein levels of Perk and phospho-Perk were found to be increased in 
Keap1-/-, but without increased downstream effects, compared to WT.  
Conversely, Nrf2-/- cells demonstrated increased levels of downstream effectors 
of Perk.   These results strongly suggest that Nrf2 modulates the activity of Perk, 
with increased Nrf2 suppressing phospho-Perk kinase activity, possibly in a 
negative feedback cycle.  Further supporting this, levels of p58IPK, a co-
chaperone protein that has an inhibitory effect of Perk, were reduced in Keap1-/-. 
 
The response to induced ER stress also varied with cellular Nrf2 status:  The 
maximal expression of UPR components induced by glucose deprivation 
occurred at 4 hours in WT cells and in Nrf2-/- cells.  Interestingly, the magnitude 
of the response was considerably smaller in Nrf2-/- cells.  Taken together, it is 
suggested that because Nrf2-/- cells have basal ER stress, they have less ability to 
respond to conditions of increased stress.   Keap1-/- cells were found to have a 
reduced response to glucose deprivation at 6hours, suggesting that longer 
conditions of ER stress are required to activate the UPR with increased 
availability of Nrf2. 
 
These results clearly demonstrate that altered Nrf2 status affects the cellular 
response to ER stress. It is proposed that Nrf2 is involved in a negative feedback 
mechanism with the UPR pathways, whereby Nrf2 activity induced by UPR 
helps to alleviate ER stress, possibly by increasing glutathione and optimising 
the ER redox environment, and increased Nrf2 down-regulates the ER response.  
This would explain why Nrf2-/- cells express increased UPR proteins under basal 
conditions, due to a lack of negative feedback.  With sustained increases in Nrf2, 
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such as in Keap1-/-, cells have conferred resistance against ER stress; however, 
the balance of the UPR pathways becomes skewed towards the Perk arm.  It is 
possible that Nrf2 has a role in the feedback mechanism by which cells are able 
to have different responses depending on the intensity and duration of ER stress, 
for example, sustained ER stress despite activation of Nrf2 may induce cells to 
go down the apoptotic pathway via Perk. 
 
4.3.1 Relevance to other work in this field 
Previous work has shown that the Nrf2/ARE pathway is induced under 
conditions of ER stress(84).  Mechanistically, this could occur either in response 
to increased ROS during ER stress, via an interaction with signalling components 
of the UPR or as a combination of these.  In similarity to our results, Cullinan 
and Diehl found that Nrf2-/- MEF cells were more sensitive to ER stress (85).  
Although they focused on the Perk arm of the UPR, and did not examine the 
other UPR markers, they found that Chop was basally increased in Nrf2-/- cells, 
in agreement with the rtPCR results of this project.  
 
Cullinan and Diehl showed that in WT cells, glucose deprivation induced the 
nuclear translocation of Nrf2 and increased mRNA of Nrf2 targets Gclc and 
Nqo1 (85).  This did not occur in Nrf2-/- cells, which displayed basally increased 
and consistently high levels of ROS and carbonyl-modified products, 
demonstrating oxidative stress.  Whereas WT cells were transient increase in 
glutathione levels under conditions of glucose starvation, glutathione rapidly 
decreased in Nrf2-/- cells, providing evidence that Nrf2 participates in the cellular 
response to ROS during ER stress.  
 
The study also demonstrated that Perk-/- cells were similarly unable to increase 
glutathione levels in response to increased ROS during ER stress, despite normal 
basal glutathione levels (85). Nuclear translocation of Nrf2 did not occur in 
response to ER stress in Perk-/- cells, and Nqo1 and Gclc were not induced (84). 
However, the addition of constitutively activated Nrf2 to Perk-/- cells was able to 
rescue Perk-/- cells.  Similarly, N-acetyl-cysteine (NAC) has been shown to 
reduce apoptosis induced by ER stress in Nrf2-/- and Perk-/- cells (84, 85).  Studies 
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in the same lab demonstrated that Nrf2 did not activate an ARE reporter in the 
presence of dominant-negative Perk and that overexpression of Perk promoted 
the nuclear translocation of Nrf2 in the absence of any ER stress inducing 
agent(84).  These findings implicate Nrf2 as a target of the Perk arm of the UPR.  
Perk-/- cells were shown to have normal basal levels of ROS and Nrf2, leading 
the authors to suggest that the main contribution of Perk to REDOX homeostasis 
occurs under conditions of ER stress (68). 
 
A study investigating the effects of chemotherapeutic alkylating agents has 
recently demonstrated an inter-relationship between Nrf2/ARE and ER stress 
pathways (35).  Drugs of the alkylating agent class were shown to promote the 
nuclear accumulation of Nrf2, as well as ARE target gene induction and UPR 
components in vitro.   
 
Alkylating agent related toxicity and caspase-3 induction were potentiated by 
Nrf2 silencing, but was supressed by both Keap1-knockdown or Nrf2 
overexpression, providing evidence that Nrf2 activation confers a protective 
advantage against these agents.  Supplementation of WT cells with the 
glutathione precursor substrates NAC or glutathione-ethyl-ester also reduced the 
toxicity of alkylating agents, whereas depletion of glutathione by the known 
inhibitor buthionine sulfoximine increased toxicity.  
 
The study found that alkylating agents caused ER stress, demonstrated by 
increased Atf6 cleavage, expression of Ire1α, phosphorylation of Perk, and 
upregulation of UPR components; Bip, Atf3 and Chop.  Inhibition of cell growth 
and caspase-3 induction due to alkylating agents were supressed by Perk 
silencing but potentiated by reduction of either Atf6 or Ire1α.  Bip 
overexpression was also shown to attenuate cytotoxicity.  The study showed that 
nuclear accumulation of Nrf2, ARE induction and glutathione biosynthesis did 
not require either Perk, Ire1α or Atf6, demonstrating that in this context, Nrf2 
activation was not a downstream component of the UPR.  Instead, Nrf2 depletion 
was found to increase the expression of ER stress markers and potentiate UPR 
induction.  Pre-treatment with NAC was found to attenuate the expression of 
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UPR components in WT cells, but was also able to attenuate increases in ER 
stress in Nrf2 depleted cells. 
 
These findings support the results herein that loss of Nrf2 activity makes cells 
more susceptible to ER stress.  These findings also suggest that Nrf2 mediated 
glutathione biosynthesis is an important factor in attenuation of alkylating agent 
induced ER stress and cytotoxicity.    
4.3.2 Further work 
This study has utilised Tm treatment and glucose starvation techniques to induce 
ER stress.  Interplay between Nrf2 and components of the UPR could be further 
assessed using additional methods for inducing ER stress.  There are further 
pharmacological agents known to induce ER stress, for example, treatment with 
thapsigargin induces ER stress by inhibition of the ER Ca2+-ATPase, an ER 
transporter that is important for many Ca2+ dependent ER chaperones (83, 86).  
 
As described in Chapter 1, NAFLD is strongly associated with perturbed lipid 
homeostasis and hyperglycaemia.  Saturated fatty acids are known to induce ER 
stress in vitro and in vivo, and hyperglycaemia has also been shown to cause ER 
stress and both induce UPR and inflammatory pathways (68, 74-77, 87-90).  
Further work to determine the role of Nrf2 in the context of ER stress induced by 
saturated fatty acids or hyperglycaemia may be of particular importance to 
understanding the pathogenesis of NAFLD. 
4.4 Conclusion 
The pathogenesis of NASH is not fully understood, but is thought to involve 
interacting mechanisms of damage, whereby insulin resistance and hepatic 
storage of triacylglycerides (resulting in steatosis) is compounded by further 
cellular insult leading to inflammation and fibrosis.  ER stress activates pathways 
of the unfolded protein response (UPR), which act to attenuate stress, adapt to 
conditions and achieve ER homeostasis.  However, if the cell is unable restore 
normal ER functioning under conditions of chronic ER stress, the sustained UPR 
interacts with other cell signalling pathways to drive the cell to apoptosis.  Both 
oxidative stress and ER stress are known to contribute to many diseases and the 
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role of cellular stress in liver disease has been a subject of much interest in recent 
years.  Cross talk between these stress response pathways is likely, and in this 
project the role of Nrf2 in ER stress has been investigated.  The UPR may have 
particular importance in NASH as the ER is involved in the regulation of 
metabolism and inflammation and protein synthesis is a major role of 
hepatocytes.  
 I 
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